nohup: ignoring input
start of process...
Processing file ./test.json
./test.json: 0it [00:00, ?it/s]./test.json: 1it [00:04,  4.95s/it]./test.json: 2it [00:09,  4.53s/it]./test.json: 3it [00:13,  4.33s/it]./test.json: 4it [00:18,  4.72s/it]./test.json: 5it [00:24,  5.03s/it]./test.json: 6it [00:28,  4.67s/it]./test.json: 7it [00:32,  4.48s/it]./test.json: 8it [00:36,  4.50s/it]./test.json: 9it [00:41,  4.42s/it]./test.json: 10it [00:45,  4.56s/it]./test.json: 11it [00:50,  4.47s/it]./test.json: 12it [00:55,  4.58s/it]./test.json: 13it [01:00,  4.94s/it]./test.json: 14it [01:06,  5.13s/it]./test.json: 15it [01:10,  4.94s/it]./test.json: 16it [01:15,  4.77s/it]./test.json: 17it [01:20,  4.95s/it]./test.json: 18it [01:25,  5.02s/it]./test.json: 19it [01:32,  5.42s/it]./test.json: 20it [01:36,  5.09s/it]./test.json: 21it [01:41,  5.18s/it]./test.json: 22it [01:46,  4.94s/it]./test.json: 23it [01:50,  4.88s/it]./test.json: 24it [01:55,  4.89s/it]./test.json: 25it [02:01,  5.17s/it]./test.json: 26it [02:06,  5.02s/it]./test.json: 27it [02:10,  4.86s/it]./test.json: 28it [02:14,  4.53s/it]./test.json: 29it [02:19,  4.71s/it]./test.json: 30it [02:25,  4.95s/it]./test.json: 31it [02:29,  4.87s/it]./test.json: 32it [02:35,  5.00s/it]./test.json: 33it [02:40,  5.13s/it]./test.json: 34it [02:46,  5.39s/it]./test.json: 35it [02:52,  5.55s/it]./test.json: 36it [02:57,  5.42s/it]./test.json: 37it [03:02,  5.30s/it]./test.json: 38it [03:07,  5.17s/it]./test.json: 39it [03:12,  5.20s/it]./test.json: 40it [03:17,  4.98s/it]./test.json: 41it [03:22,  5.13s/it]./test.json: 42it [03:27,  5.10s/it]./test.json: 43it [03:32,  5.01s/it]./test.json: 44it [03:37,  5.02s/it]./test.json: 45it [03:42,  4.84s/it]./test.json: 46it [03:47,  4.90s/it]./test.json: 47it [03:51,  4.72s/it]./test.json: 48it [03:56,  4.77s/it]./test.json: 49it [04:01,  4.83s/it]./test.json: 50it [04:06,  4.99s/it]./test.json: 51it [04:11,  4.82s/it]./test.json: 52it [04:14,  4.52s/it]./test.json: 53it [04:20,  4.88s/it]./test.json: 54it [04:24,  4.72s/it]./test.json: 55it [04:29,  4.57s/it]./test.json: 56it [04:33,  4.55s/it]./test.json: 57it [04:38,  4.51s/it]./test.json: 58it [04:42,  4.45s/it]./test.json: 59it [04:46,  4.37s/it]./test.json: 60it [04:51,  4.58s/it]./test.json: 61it [04:56,  4.78s/it]./test.json: 62it [05:02,  5.02s/it]./test.json: 63it [05:07,  5.05s/it]./test.json: 64it [05:12,  4.96s/it]./test.json: 65it [05:16,  4.78s/it]./test.json: 66it [05:22,  5.09s/it]./test.json: 67it [05:27,  5.19s/it]./test.json: 68it [05:34,  5.72s/it]./test.json: 69it [05:40,  5.62s/it]./test.json: 70it [05:44,  5.33s/it]./test.json: 71it [05:49,  5.05s/it]./test.json: 72it [05:53,  4.85s/it]./test.json: 73it [05:58,  4.74s/it]./test.json: 74it [06:01,  4.37s/it]./test.json: 75it [06:05,  4.25s/it]./test.json: 76it [06:09,  4.11s/it]./test.json: 77it [06:13,  4.10s/it]./test.json: 78it [06:16,  3.83s/it]./test.json: 79it [06:20,  3.76s/it]./test.json: 80it [06:24,  3.83s/it]./test.json: 81it [06:28,  3.89s/it]./test.json: 82it [06:32,  3.93s/it]./test.json: 83it [06:36,  4.13s/it]./test.json: 84it [06:41,  4.37s/it]./test.json: 85it [06:46,  4.40s/it]./test.json: 86it [06:50,  4.38s/it]./test.json: 87it [06:58,  5.35s/it]./test.json: 88it [07:03,  5.22s/it]./test.json: 89it [07:08,  5.33s/it]./test.json: 90it [07:12,  4.97s/it]./test.json: 91it [07:17,  4.74s/it]./test.json: 92it [07:22,  4.84s/it]./test.json: 93it [07:27,  4.92s/it]./test.json: 94it [07:34,  5.49s/it]./test.json: 95it [07:38,  5.08s/it]./test.json: 96it [07:42,  4.68s/it]./test.json: 97it [07:48,  5.27s/it]./test.json: 98it [07:55,  5.60s/it]./test.json: 99it [08:01,  5.79s/it]./test.json: 100it [08:07,  5.86s/it]./test.json: 101it [08:14,  6.14s/it]./test.json: 102it [08:20,  6.28s/it]./test.json: 103it [08:27,  6.57s/it]./test.json: 104it [08:34,  6.51s/it]./test.json: 105it [08:39,  6.00s/it]./test.json: 106it [08:46,  6.31s/it]./test.json: 107it [08:52,  6.44s/it]./test.json: 108it [08:58,  6.19s/it]./test.json: 109it [09:04,  6.03s/it]./test.json: 110it [09:11,  6.42s/it]./test.json: 111it [09:17,  6.26s/it]./test.json: 112it [09:23,  6.12s/it]./test.json: 113it [09:29,  6.27s/it]./test.json: 114it [09:35,  6.17s/it]./test.json: 115it [09:42,  6.28s/it]./test.json: 116it [09:47,  6.10s/it]./test.json: 117it [09:52,  5.67s/it]./test.json: 118it [09:58,  5.80s/it]./test.json: 119it [10:06,  6.26s/it]./test.json: 120it [10:11,  6.15s/it]./test.json: 121it [10:15,  5.46s/it]./test.json: 122it [10:20,  5.27s/it]./test.json: 123it [10:26,  5.30s/it]./test.json: 124it [10:31,  5.29s/it]./test.json: 125it [10:36,  5.29s/it]./test.json: 126it [10:41,  5.05s/it]./test.json: 127it [10:46,  5.08s/it]./test.json: 128it [10:51,  5.13s/it]./test.json: 129it [10:57,  5.29s/it]./test.json: 130it [11:02,  5.27s/it]./test.json: 131it [11:07,  5.16s/it]./test.json: 132it [11:12,  5.17s/it]./test.json: 133it [11:16,  4.81s/it]./test.json: 134it [11:22,  5.21s/it]./test.json: 135it [11:27,  5.22s/it]./test.json: 136it [11:33,  5.33s/it]./test.json: 137it [11:41,  6.16s/it]./test.json: 138it [11:46,  5.89s/it]./test.json: 139it [11:51,  5.66s/it]./test.json: 140it [11:57,  5.59s/it]./test.json: 140it [11:57,  5.12s/it]
HTTPSConnectionPool(host='translate.google.com', port=443): Max retries exceeded with url: /m?q=Ustekinumab,+a+human+monoclonal+IgG1+antibody+targeting+the+p40-subunit+shared+by+interleukin+(IL)12+and+IL-23,+represents+a+potential+treatment+for+atopic+dermatitis+(AD).&tl=zh-CN&sl=en (Caused by ProxyError('Cannot connect to proxy.', ConnectionResetError(104, 'Connection reset by peer'))) Ustekinumab, a human monoclonal IgG1 antibody targeting the p40-subunit shared by interleukin (IL)12 and IL-23, represents a potential treatment for atopic dermatitis (AD).
Processing file ./dev.json
./dev.json: 0it [00:00, ?it/s]./dev.json: 1it [00:05,  5.45s/it]./dev.json: 2it [00:10,  4.96s/it]./dev.json: 3it [00:15,  4.95s/it]./dev.json: 4it [00:20,  5.12s/it]./dev.json: 5it [00:25,  5.20s/it]./dev.json: 6it [00:29,  4.76s/it]./dev.json: 7it [00:35,  5.06s/it]./dev.json: 8it [00:40,  4.98s/it]./dev.json: 9it [00:44,  4.86s/it]./dev.json: 10it [00:49,  4.77s/it]./dev.json: 11it [00:53,  4.56s/it]./dev.json: 12it [00:57,  4.36s/it]./dev.json: 13it [01:01,  4.44s/it]./dev.json: 14it [01:07,  4.73s/it]./dev.json: 15it [01:11,  4.50s/it]./dev.json: 16it [01:14,  4.16s/it]./dev.json: 17it [01:19,  4.25s/it]./dev.json: 18it [01:24,  4.54s/it]./dev.json: 19it [01:29,  4.65s/it]./dev.json: 20it [01:33,  4.50s/it]./dev.json: 21it [01:37,  4.44s/it]./dev.json: 22it [01:42,  4.42s/it]./dev.json: 23it [01:46,  4.37s/it]./dev.json: 24it [01:49,  4.16s/it]./dev.json: 25it [01:54,  4.36s/it]./dev.json: 26it [01:58,  4.15s/it]./dev.json: 27it [02:05,  4.92s/it]./dev.json: 28it [02:10,  4.91s/it]./dev.json: 29it [02:15,  5.13s/it]./dev.json: 30it [02:20,  5.17s/it]./dev.json: 31it [02:25,  4.92s/it]./dev.json: 32it [02:30,  4.92s/it]./dev.json: 33it [02:34,  4.82s/it]./dev.json: 34it [02:40,  4.97s/it]./dev.json: 35it [02:44,  4.75s/it]./dev.json: 36it [02:50,  5.11s/it]./dev.json: 37it [02:53,  4.68s/it]./dev.json: 38it [02:57,  4.39s/it]./dev.json: 39it [03:01,  4.35s/it]./dev.json: 40it [03:05,  4.09s/it]./dev.json: 41it [03:09,  3.99s/it]./dev.json: 42it [03:14,  4.40s/it]./dev.json: 43it [03:20,  4.77s/it]./dev.json: 44it [03:24,  4.69s/it]./dev.json: 45it [03:28,  4.56s/it]./dev.json: 46it [03:33,  4.56s/it]./dev.json: 47it [03:37,  4.25s/it]./dev.json: 48it [03:41,  4.39s/it]./dev.json: 49it [03:46,  4.57s/it]./dev.json: 50it [03:50,  4.22s/it]./dev.json: 51it [03:55,  4.57s/it]./dev.json: 52it [03:59,  4.49s/it]./dev.json: 53it [04:05,  4.75s/it]./dev.json: 54it [04:11,  5.17s/it]./dev.json: 55it [04:17,  5.46s/it]./dev.json: 56it [04:21,  5.13s/it]./dev.json: 57it [04:27,  5.16s/it]./dev.json: 58it [04:32,  5.24s/it]./dev.json: 59it [04:39,  5.80s/it]./dev.json: 60it [04:44,  5.45s/it]./dev.json: 61it [04:49,  5.28s/it]./dev.json: 62it [04:56,  5.88s/it]./dev.json: 63it [05:00,  5.32s/it]./dev.json: 64it [05:07,  5.73s/it]./dev.json: 65it [05:12,  5.57s/it]./dev.json: 66it [05:16,  5.13s/it]./dev.json: 67it [05:22,  5.48s/it]./dev.json: 68it [05:27,  5.20s/it]./dev.json: 69it [05:31,  4.95s/it]./dev.json: 70it [05:36,  4.85s/it]./dev.json: 71it [05:42,  5.17s/it]./dev.json: 72it [05:47,  5.13s/it]./dev.json: 73it [05:53,  5.48s/it]./dev.json: 74it [05:58,  5.40s/it]./dev.json: 75it [06:03,  5.10s/it]./dev.json: 75it [06:03,  4.84s/it]
Processing file ./train.json
./train.json: 0it [00:00, ?it/s]./train.json: 1it [00:05,  5.84s/it]./train.json: 2it [00:10,  5.03s/it]./train.json: 3it [00:14,  4.82s/it]./train.json: 4it [00:19,  4.56s/it]./train.json: 5it [00:22,  4.33s/it]./train.json: 6it [00:28,  4.89s/it]./train.json: 7it [00:35,  5.36s/it]./train.json: 8it [00:39,  4.94s/it]./train.json: 9it [00:43,  4.68s/it]./train.json: 10it [00:48,  4.74s/it]./train.json: 11it [00:53,  4.85s/it]./train.json: 12it [00:58,  4.89s/it]./train.json: 13it [01:04,  5.12s/it]./train.json: 14it [01:10,  5.38s/it]./train.json: 15it [01:15,  5.31s/it]./train.json: 16it [01:19,  4.94s/it]./train.json: 17it [01:23,  4.73s/it]./train.json: 18it [01:29,  5.09s/it]./train.json: 19it [01:34,  5.00s/it]./train.json: 20it [01:39,  4.99s/it]./train.json: 21it [01:42,  4.58s/it]./train.json: 22it [01:47,  4.48s/it]./train.json: 23it [01:53,  4.94s/it]./train.json: 24it [01:59,  5.48s/it]./train.json: 25it [02:05,  5.46s/it]./train.json: 26it [02:09,  5.22s/it]./train.json: 27it [02:15,  5.46s/it]./train.json: 28it [02:19,  4.86s/it]./train.json: 29it [02:22,  4.50s/it]./train.json: 30it [02:28,  4.66s/it]./train.json: 31it [02:32,  4.60s/it]./train.json: 32it [02:37,  4.63s/it]./train.json: 33it [02:42,  4.91s/it]./train.json: 34it [02:47,  4.81s/it]./train.json: 35it [02:51,  4.59s/it]./train.json: 36it [02:57,  4.94s/it]./train.json: 37it [03:01,  4.74s/it]./train.json: 38it [03:05,  4.63s/it]./train.json: 39it [03:09,  4.37s/it]./train.json: 40it [03:13,  4.09s/it]./train.json: 41it [03:17,  4.27s/it]./train.json: 42it [03:24,  4.98s/it]./train.json: 43it [03:29,  5.03s/it]./train.json: 44it [03:34,  5.00s/it]./train.json: 45it [03:38,  4.63s/it]./train.json: 46it [03:43,  4.97s/it]./train.json: 47it [03:48,  4.95s/it]./train.json: 48it [03:54,  5.19s/it]./train.json: 49it [03:59,  5.18s/it]./train.json: 50it [04:05,  5.22s/it]./train.json: 51it [04:09,  5.07s/it]./train.json: 52it [04:16,  5.42s/it]./train.json: 53it [04:22,  5.66s/it]./train.json: 54it [04:27,  5.58s/it]./train.json: 55it [04:33,  5.67s/it]./train.json: 56it [04:39,  5.83s/it]./train.json: 57it [04:43,  5.23s/it]./train.json: 58it [04:48,  5.30s/it]./train.json: 59it [04:54,  5.25s/it]./train.json: 60it [04:58,  4.94s/it]./train.json: 61it [05:01,  4.37s/it]./train.json: 62it [05:05,  4.32s/it]./train.json: 63it [05:10,  4.64s/it]./train.json: 64it [05:15,  4.58s/it]./train.json: 65it [05:22,  5.26s/it]./train.json: 66it [05:27,  5.34s/it]./train.json: 67it [05:32,  5.01s/it]./train.json: 68it [05:38,  5.56s/it]./train.json: 69it [05:44,  5.64s/it]./train.json: 70it [05:49,  5.25s/it]./train.json: 71it [05:53,  5.16s/it]./train.json: 72it [05:59,  5.27s/it]./train.json: 73it [06:03,  4.84s/it]./train.json: 74it [06:08,  4.85s/it]./train.json: 75it [06:14,  5.18s/it]./train.json: 76it [06:19,  5.23s/it]./train.json: 77it [06:24,  5.05s/it]./train.json: 78it [06:28,  4.89s/it]./train.json: 79it [06:32,  4.64s/it]./train.json: 80it [06:36,  4.33s/it]./train.json: 81it [06:40,  4.19s/it]./train.json: 82it [06:44,  4.24s/it]./train.json: 83it [06:48,  4.18s/it]./train.json: 84it [06:52,  4.07s/it]./train.json: 85it [06:55,  3.93s/it]./train.json: 86it [07:01,  4.39s/it]./train.json: 87it [07:06,  4.60s/it]./train.json: 88it [07:11,  4.58s/it]./train.json: 89it [07:15,  4.66s/it]./train.json: 90it [07:21,  4.95s/it]./train.json: 91it [07:26,  4.91s/it]./train.json: 92it [07:31,  4.98s/it]./train.json: 93it [07:35,  4.83s/it]./train.json: 94it [07:41,  4.92s/it]./train.json: 95it [07:45,  4.85s/it]./train.json: 96it [07:51,  5.05s/it]./train.json: 97it [07:55,  4.71s/it]./train.json: 98it [08:01,  5.31s/it]./train.json: 99it [08:08,  5.72s/it]./train.json: 100it [08:14,  5.92s/it]./train.json: 101it [08:18,  5.11s/it]./train.json: 102it [08:22,  4.95s/it]./train.json: 103it [08:27,  4.79s/it]./train.json: 104it [08:31,  4.70s/it]./train.json: 105it [08:35,  4.49s/it]./train.json: 106it [08:39,  4.37s/it]./train.json: 107it [08:44,  4.53s/it]./train.json: 108it [08:49,  4.59s/it]./train.json: 109it [08:54,  4.82s/it]./train.json: 110it [09:00,  5.01s/it]./train.json: 111it [09:04,  4.72s/it]./train.json: 112it [09:08,  4.66s/it]./train.json: 113it [09:13,  4.58s/it]./train.json: 114it [09:18,  4.65s/it]./train.json: 115it [09:23,  4.84s/it]./train.json: 116it [09:27,  4.80s/it]./train.json: 117it [09:33,  4.99s/it]./train.json: 118it [09:38,  4.97s/it]./train.json: 119it [09:41,  4.44s/it]./train.json: 120it [09:45,  4.28s/it]./train.json: 121it [09:49,  4.11s/it]./train.json: 122it [09:54,  4.40s/it]./train.json: 123it [10:00,  4.97s/it]./train.json: 124it [10:04,  4.69s/it]./train.json: 125it [10:08,  4.48s/it]HTTPSConnectionPool(host='translate.google.com', port=443): Max retries exceeded with url: /m?q=Can+SUMO+affect+calcium+homeostasis?&tl=zh-CN&sl=en (Caused by SSLError(SSLEOFError(8, 'EOF occurred in violation of protocol (_ssl.c:1131)'))) Can SUMO affect calcium homeostasis?
HTTPSConnectionPool(host='translate.google.com', port=443): Max retries exceeded with url: /m?q=Charcot-Marie-Tooth+disease+type+2D+is+a+hereditary+axonal+and+glycyl-tRNA+synthetase+(GARS)-associated+neuropathy+that+is+caused+by+a+mutation+in+GARS.++Mutations+in+the+GARS+gene+cause+Charcot-Marie-Tooth+2D+and+distal+spinal+muscular+atrophy+type+V+-+allelic+disorders+characterized+by+predominantly+distal+upper+extremity+weakness+and+atrophy,+typically+beginning+during+the+second+decade+of+life.++Charcot-Marie-Tooth+disease+type+2D+(CMT2D)+is+a+dominantly+inherited+peripheral+neuropathy+caused+by+missense+mutations+in+the+glycyl-tRNA+synthetase+gene+(GARS).+The+13+genes+known+to+be+associated+with+the+CMT2+subtypes+are+KIF1B+(CMT2A1),+MFN2+(CMT2A2),+RAB7A+(formerly+RAB7)+(CMT2B),+LMNA+(CMT2B1),+MED25+(CMT2B2),+TRPV4+(CMTC),+GARS+(CMT2D),+NEFL+(CMT2E/1F),+HSPB1+(CMT2F),+MPZ+(CMT2I/J),+GDAP1+(CMT2H/K),+HSPB8+(CMT2L),+and+AARS+(CMT2N).+++The+diagnosis+of+GARS-associated+axonal+neuropathy+is+based+on+clinical+findings,+electromyography+(EMG),+and+molecular+genetic+testing+of+GARS,+encoding+glycyl-tRNA+synthetase.+Sporadic+juvenile+muscular+atrophy+of+the+distal+upper+extremity+or+Hirayama's+disease+(HD)+and+autosomal+dominant+motor+distal+neuronopathy/axonopathy+(CMT2D/dSMA-V),+produced+by+glycyl-tRNA+synthetase+(GARS)+gene+mutations,+share+some+clinical+features+including:+young+age+of+onset,+predilection+for+the+distal+upper+extremity,+asymmetry,+sparing+of+proximal+muscles+and+unusual+cold+sensitivity.++Distal+hereditary+motor+neuropathy+type+V+(dHMN-V)+and+Charcot-Marie-Tooth+syndrome+(CMT)+type+2+presenting+with+predominant+hand+involvement,+also+known+as+CMT2D+and+Silver+syndrome+(SS)+are+rare+phenotypically+overlapping+diseases+which+can+be+caused+by+mutations+in+the+Berardinelli-Seip+Congenital+Lipodystrophy+2+(BSCL2)+and+in+the+glycyl-tRNA+synthetase+encoding+(GARS)+genes.++We+previously+implicated+mutations+in+the+gene+encoding+glycyl-tRNA+synthetase+(GARS)+as+the+cause+of+CMT2D+and+dSMA-V.+Of+the+many+inherited+Charcot-Marie-Tooth+peripheral+neuropathies,+type+2D+(CMT2D)+is+caused+by+dominant+point+mutations+in+the+gene+GARS,+encoding+glycyl+tRNA+synthetase+(GlyRS).++Missense+mutations+in+the+glycyl-tRNA+synthetase+(GARS)+gene+have+been+recently+reported+in+families+with+either+dHMN-V,+CMT2D,+or+both.+Based+on+the+presence+or+absence+of+sensory+changes,+the+disease+phenotype+was+initially+defined+as+distal+spinal+muscular+atrophy+type+V+(dSMA-V)+in+three+families,+Charcot-Marie-Tooth+disease+type+2D+(CMT2D)+in+a+single+family,+and+as+either+dSMA-V+or+CMT2D+in+patients+of+another+large+family.+Linkage+to+chromosome+7p15+and+the+presence+of+disease-associated+heterozygous+GARS+mutations+have+been+identified+in+patients+from+each+of+the+five+studied+families.&tl=zh-CN&sl=en (Caused by SSLError(SSLEOFError(8, 'EOF occurred in violation of protocol (_ssl.c:1131)'))) Charcot-Marie-Tooth disease type 2D is a hereditary axonal and glycyl-tRNA synthetase (GARS)-associated neuropathy that is caused by a mutation in GARS.  Mutations in the GARS gene cause Charcot-Marie-Tooth 2D and distal spinal muscular atrophy type V - allelic disorders characterized by predominantly distal upper extremity weakness and atrophy, typically beginning during the second decade of life.  Charcot-Marie-Tooth disease type 2D (CMT2D) is a dominantly inherited peripheral neuropathy caused by missense mutations in the glycyl-tRNA synthetase gene (GARS). The 13 genes known to be associated with the CMT2 subtypes are KIF1B (CMT2A1), MFN2 (CMT2A2), RAB7A (formerly RAB7) (CMT2B), LMNA (CMT2B1), MED25 (CMT2B2), TRPV4 (CMTC), GARS (CMT2D), NEFL (CMT2E/1F), HSPB1 (CMT2F), MPZ (CMT2I/J), GDAP1 (CMT2H/K), HSPB8 (CMT2L), and AARS (CMT2N).   The diagnosis of GARS-associated axonal neuropathy is based on clinical findings, electromyography (EMG), and molecular genetic testing of GARS, encoding glycyl-tRNA synthetase. Sporadic juvenile muscular atrophy of the distal upper extremity or Hirayama's disease (HD) and autosomal dominant motor distal neuronopathy/axonopathy (CMT2D/dSMA-V), produced by glycyl-tRNA synthetase (GARS) gene mutations, share some clinical features including: young age of onset, predilection for the distal upper extremity, asymmetry, sparing of proximal muscles and unusual cold sensitivity.  Distal hereditary motor neuropathy type V (dHMN-V) and Charcot-Marie-Tooth syndrome (CMT) type 2 presenting with predominant hand involvement, also known as CMT2D and Silver syndrome (SS) are rare phenotypically overlapping diseases which can be caused by mutations in the Berardinelli-Seip Congenital Lipodystrophy 2 (BSCL2) and in the glycyl-tRNA synthetase encoding (GARS) genes.  We previously implicated mutations in the gene encoding glycyl-tRNA synthetase (GARS) as the cause of CMT2D and dSMA-V. Of the many inherited Charcot-Marie-Tooth peripheral neuropathies, type 2D (CMT2D) is caused by dominant point mutations in the gene GARS, encoding glycyl tRNA synthetase (GlyRS).  Missense mutations in the glycyl-tRNA synthetase (GARS) gene have been recently reported in families with either dHMN-V, CMT2D, or both. Based on the presence or absence of sensory changes, the disease phenotype was initially defined as distal spinal muscular atrophy type V (dSMA-V) in three families, Charcot-Marie-Tooth disease type 2D (CMT2D) in a single family, and as either dSMA-V or CMT2D in patients of another large family. Linkage to chromosome 7p15 and the presence of disease-associated heterozygous GARS mutations have been identified in patients from each of the five studied families.
HTTPSConnectionPool(host='translate.google.com', port=443): Max retries exceeded with url: /m?q=ALM+is+the+most+common+type+of+melanoma+amongst+Asians,+Africans,+ALM+develops+on+palmar,+plantar,+and+subungual+skin,+and+its+biology+is+different+from+that+of+other+cutaneous+melanomas,+where+sunlight+is+the+major+known+environmental+determinant+We+present+four+albinos+with+histologic+diagnoses+of+skin+cancer+Four+Nigerian+albinos+(two+men+and+two+women)+with+skin+cancer+The+sites+of+the+lesions+included+the+head+%5Bsquamous+cell+carcinoma+(SCC)+in+two+patients+and+basal+cell+carcinoma+(BCC)+in+one+patient%5D+and+the+upper+limb+(melanoma+wenty-nine+patients+(18+males+and+11+females)+with+skin+cancer+were+identified+Kaposi+sarcoma+associated+with+HIV+represented+81.8+percent+of+KS+cases+found.+Squamous+cell+carcinoma+(SCC)+ranked+second+and+malignant+melanoma+third+Earlier+studies+have+shown+frequent+mutations+in+the+BRAF+and+NRAS+genes+in+cutaneous+melanoma,+but+these+alterations+have+not+been+examined+in+the+rare+category+of+melanoma+from+black+Africans.+In+a+series+of+melanomas+from+black+Africans+(n%3D26),+only+two+BRAF+mutations+(8%25)+were+found,+both+being+different+from+the+common+T1799A+substitution.+Moreover,+melanomas+from+black+Africans+exhibited+mutations+in+NRAS+exon+1+only+(12%25),+whereas+NRAS+exon+2+mutations+were+predominant+in+melanomas+from+Caucasians.+Thus,+the+frequencies+of+BRAF+and+NRAS+mutations+were+particularly+low+in+melanomas+from+black+Africans,+supporting+a+different+pathogenesis+of+these+tumors.+Malignant+melanoma+(MM)+remains+a+pediatric+rarity+world-wide,+but+perhaps+more+so+in+black+Africans.+To+the+best+of+our+knowledge,+the+current+report+of+MM+in+a+two-and-a-half-year-old+Nigerian+who+had+a+pre-existing+congenital+giant+hairy+nevus+is+probably+the+first+(in+an+accessible+literature)+in+a+black+African+child.+Malignant+melanomas+in+black+Africans+are+predominantly+located+on+the+lower+extremities+Thus,+our+findings+indicate+that+melanomas+located+on+the+lower+extremities+in+black+Africans+show+several+features+of+aggressiveness;+in+particular,+the+proliferative+activity+was+high,+and+p16+alterations+was+frequent+as+evidenced+by+loss+of+protein+staining.+Our+findings+also+indicated+that+the+diagnosis+is+delayed+among+black+Africans.+Africans+with+dark+skin+have+a+reduced+risk+of+getting+all+types+of+skin+cancer+as+compared+with+Caucasians,+but+the+ratio+of+their+incidence+rates+of+cutaneous+malignant+melanoma+to+that+of+squamous+cell+carcinoma+is+larger+than+the+corresponding+ratio+for+Caucasians.+(+Albino+Africans,+as+compared+with+normally+pigmented+Africans,+seem+to+have+a+relatively+small+risk+of+getting+cutaneous+malignant+melanomas+compared+to+nonmelanomas.+This+is+probably+also+true+for+albino+and+normally+pigmented+Caucasians.+Scant+data+exists+on+melanoma+in+blacks+from+Africa+The+mean+age+at+presentation+of+the+39+women+and+24+men+was+60.5+years+(range+of+30+to+85+years),+with+a+peak+incidence+in+the+sixth+decade.+The+foot+was+the+most+common+site+of+disease+(45+patients).+Seven+patients+had+subungual+melanoma,+seven+had+primary+mucosal+lesions,+and+in+six,+the+primary+lesion+could+not+be+found.+The+poor+prognosis+in+black+patients+in+South+Africa+is+the+result+of+delayed+presentation+with+thick+primary+lesions+and+advanced+disease+The+outcome+of+treatment+in+40+black+patients+(27+women,+13+men;+mean+age+62.9+years)+with+plantar+melanoma+over+a+13-year+period+was+analysed+Delay+in+presentation+and+locally+advanced+disease+may+explain+the+poor+prognosis+of+plantar+melanoma+in+black+South+Africans.+Eighteen+cases+of+malignant+skin+tumors+seen+at+the+University+of+Port+Harcourt+Teaching+Hospital+over+3+years+(1984+to+1987)+were+analyzed+for+diagnoses,+site+of+tumors,+sex,+and+age.+Seven+patients+(39%25)+had+malignant+melanomas+affecting+only+the+soles+of+the+feet,+while+the+same+number+had+squamous+cell+carcinomas+widely+distributed+in+various+parts+of+the+body+Non-white+populations+experienced+in+general+a+much+lower+incidence+of+melanoma+although+there+was+some+overlap+of+white+and+non-white+rates.+Populations+of+African+descent+were+found+to+have+a+higher+incidence+than+those+of+Asiatic+origin,+but+it+was+concluded+that+this+was+due+largely+to+the+high+frequency+of+tumours+among+Africans+on+the+sole+of+the+foot.+Pathological+features+of+twenty-one+cases+of+malignant+melanoma+studied+in+the+University+of+Nigeria+Teaching+Hospital,+Enugu+during+the+period+January,+1974+to+December,+1975+are+presented.+Malignant+melanoma+accounted+for+2.4%25+of+all+tumours+and+4.5%25+of+all+malignant+tumours,+greatest+age+incidence+being+in+the+fifth+to+seventh+decades.+81%25+melanomas+occurred+on+the+sole+of+feet+validating+the+hypothesis+that+the+pigmented+skin+in+Africans+is+resistant+to+malignant+melanoma.+This+paper+reports+the+incidence+of+this+lesion+in+association+with+invasive+malignant+melanomas+of+the+feet+and+hands+of+Black+Africans.+Follow-up+data+(over+a+3-year+period)+and+the+histological+appearances+of+primary+lesion+were+studied+and+related+in+40+Black+patients+with+malignant+melanoma.+Malignant+melanoma+of+the+skin+in+Blacks+in+formidable+and+sinister+tumour.+The+incidence+of+malignant+melanoma+in+Johannesburg+Black+was+1,2+per+100+000+and+accounted+for+2%25+of+all+cancers.+The+largest+number+of+cases+occurred+in+the+50-+70-year+age+group+and+there+was+a+female+preponderance.+As+in+previous+studies,+the+sites+predominantly+affected+were+the+foot+and+the+hand,+mainly+on+the+plantar+and+palmar+surfaces.+Twenty-one+cases+of+malignant+melanoma+occurring+in+the+Igbos+of+Nigeria+have+been+analysed.+The+site+of+predilection+is+the+sole+of+the+foot.+This+result+supports+the+conclusion+that+Negroes+tend+to+have+the+disease+in+the+non-pigmented+parts.+A+case+of+leptomeningeal+melanoma+in+an+African+child+of+7+years+is+presented+together+with+a+survey+of+pigmentation+in+the+normal+African+brain.&tl=zh-CN&sl=en (Caused by SSLError(SSLEOFError(8, 'EOF occurred in violation of protocol (_ssl.c:1131)'))) ./train.json: 126it [10:12,  4.34s/it]./train.json: 127it [10:16,  4.11s/it]./train.json: 128it [10:21,  4.41s/it]ALM is the most common type of melanoma amongst Asians, Africans, ALM develops on palmar, plantar, and subungual skin, and its biology is different from that of other cutaneous melanomas, where sunlight is the major known environmental determinant We present four albinos with histologic diagnoses of skin cancer Four Nigerian albinos (two men and two women) with skin cancer The sites of the lesions included the head [squamous cell carcinoma (SCC) in two patients and basal cell carcinoma (BCC) in one patient] and the upper limb (melanoma wenty-nine patients (18 males and 11 females) with skin cancer were identified Kaposi sarcoma associated with HIV represented 81.8 percent of KS cases found. Squamous cell carcinoma (SCC) ranked second and malignant melanoma third Earlier studies have shown frequent mutations in the BRAF and NRAS genes in cutaneous melanoma, but these alterations have not been examined in the rare category of melanoma from black Africans. In a series of melanomas from black Africans (n=26), only two BRAF mutations (8%) were found, both being different from the common T1799A substitution. Moreover, melanomas from black Africans exhibited mutations in NRAS exon 1 only (12%), whereas NRAS exon 2 mutations were predominant in melanomas from Caucasians. Thus, the frequencies of BRAF and NRAS mutations were particularly low in melanomas from black Africans, supporting a different pathogenesis of these tumors. Malignant melanoma (MM) remains a pediatric rarity world-wide, but perhaps more so in black Africans. To the best of our knowledge, the current report of MM in a two-and-a-half-year-old Nigerian who had a pre-existing congenital giant hairy nevus is probably the first (in an accessible literature) in a black African child. Malignant melanomas in black Africans are predominantly located on the lower extremities Thus, our findings indicate that melanomas located on the lower extremities in black Africans show several features of aggressiveness; in particular, the proliferative activity was high, and p16 alterations was frequent as evidenced by loss of protein staining. Our findings also indicated that the diagnosis is delayed among black Africans. Africans with dark skin have a reduced risk of getting all types of skin cancer as compared with Caucasians, but the ratio of their incidence rates of cutaneous malignant melanoma to that of squamous cell carcinoma is larger than the corresponding ratio for Caucasians. ( Albino Africans, as compared with normally pigmented Africans, seem to have a relatively small risk of getting cutaneous malignant melanomas compared to nonmelanomas. This is probably also true for albino and normally pigmented Caucasians. Scant data exists on melanoma in blacks from Africa The mean age at presentation of the 39 women and 24 men was 60.5 years (range of 30 to 85 years), with a peak incidence in the sixth decade. The foot was the most common site of disease (45 patients). Seven patients had subungual melanoma, seven had primary mucosal lesions, and in six, the primary lesion could not be found. The poor prognosis in black patients in South Africa is the result of delayed presentation with thick primary lesions and advanced disease The outcome of treatment in 40 black patients (27 women, 13 men; mean age 62.9 years) with plantar melanoma over a 13-year period was analysed Delay in presentation and locally advanced disease may explain the poor prognosis of plantar melanoma in black South Africans. Eighteen cases of malignant skin tumors seen at the University of Port Harcourt Teaching Hospital over 3 years (1984 to 1987) were analyzed for diagnoses, site of tumors, sex, and age. Seven patients (39%) had malignant melanomas affecting only the soles of the feet, while the same number had squamous cell carcinomas widely distributed in various parts of the body Non-white populations experienced in general a much lower incidence of melanoma although there was some overlap of white and non-white rates. Populations of African descent were found to have a higher incidence than those of Asiatic origin, but it was concluded that this was due largely to the high frequency of tumours among Africans on the sole of the foot. Pathological features of twenty-one cases of malignant melanoma studied in the University of Nigeria Teaching Hospital, Enugu during the period January, 1974 to December, 1975 are presented. Malignant melanoma accounted for 2.4% of all tumours and 4.5% of all malignant tumours, greatest age incidence being in the fifth to seventh decades. 81% melanomas occurred on the sole of feet validating the hypothesis that the pigmented skin in Africans is resistant to malignant melanoma. This paper reports the incidence of this lesion in association with invasive malignant melanomas of the feet and hands of Black Africans. Follow-up data (over a 3-year period) and the histological appearances of primary lesion were studied and related in 40 Black patients with malignant melanoma. Malignant melanoma of the skin in Blacks in formidable and sinister tumour. The incidence of malignant melanoma in Johannesburg Black was 1,2 per 100 000 and accounted for 2% of all cancers. The largest number of cases occurred in the 50- 70-year age group and there was a female preponderance. As in previous studies, the sites predominantly affected were the foot and the hand, mainly on the plantar and palmar surfaces. Twenty-one cases of malignant melanoma occurring in the Igbos of Nigeria have been analysed. The site of predilection is the sole of the foot. This result supports the conclusion that Negroes tend to have the disease in the non-pigmented parts. A case of leptomeningeal melanoma in an African child of 7 years is presented together with a survey of pigmentation in the normal African brain.
./train.json: 129it [10:25,  4.27s/it]./train.json: 130it [10:32,  5.08s/it]./train.json: 131it [10:36,  4.72s/it]./train.json: 132it [10:39,  4.48s/it]./train.json: 133it [10:45,  4.93s/it]./train.json: 134it [10:51,  5.22s/it]./train.json: 135it [10:58,  5.57s/it]./train.json: 136it [11:01,  4.80s/it]./train.json: 137it [11:06,  4.80s/it]./train.json: 138it [11:11,  5.07s/it]./train.json: 139it [11:17,  5.33s/it]./train.json: 140it [11:22,  5.28s/it]HTTPSConnectionPool(host='translate.google.com', port=443): Max retries exceeded with url: /m?q=Treatment+for+14+days+with+70+mg/kg+per+day+venlafaxine,+which+inhibits+both+the+NET+and+SERT,+or+10+mg/kg+per+day+phenelzine,+a+monoamine+oxidase+inhibitor,+produced+antidepressant-like+effects+on+behavior+without+altering+NET+or+SERT+expression.+Venlafaxine+blocks+both+serotonin+and+norepinephrine+transporters+(SERT+and+NET),+with+higher+affinity+for+SERT.+Chronic+venlafaxine+treatment+affected+SERT+and+NET+binding+differently+from+paroxetine+or+desipramine.+Venlafaxine+blocks+both+serotonin+and+norepinephrine+transporters+(SERT+and+NET),+with+higher+affinity+for+SERT+Paroxetine+and+venlafaxine+are+potent+serotonin+transporter+(SERT)+antagonists+and+weaker+norepinephrine+transporter+(NET)+antagonists+Using+a+novel+blood+assay+that+estimates+CNS+transporter+occupancy+we+estimated+the+relative+SERT+and+NET+occupancy+of+paroxetine+and+venlafaxine+in+human+subjects+to+assess+the+relative+magnitude+of+SERT+and+NET+inhibition+Treatment+for+14+days+with+70+mg/kg+per+day+venlafaxine,+which+inhibits+both+the+NET+and+SERT,+or+10+mg/kg+per+day+phenelzine,+a+monoamine+oxidase+inhibitor,+produced+antidepressant-like+effects+on+behavior+without+altering+NET+or+SERT+expression+We+then+performed+the+first+reported+investigation+of+epistasis+between+the+SERT+gene+and+norepinephrine+transporter+gene+(SLC6A2,+alias+NET)+in+AN,+as+an+earlier+study+suggested+that+atypical+AN+responds+to+the+dual+serotonin-norepinephrine+reuptake+inhibitor+venlafaxine+Of+particular+interest+were+the+findings+that+paroxetine,+generally+thought+of+as+a+selective+SERT+antagonist,+possesses+moderately+high+affinity+for+the+NET+and+that+venlafaxine,+which+has+been+described+as+a+%26quot;dual+uptake+inhibitor%26quot;,+possesses+weak+affinity+for+the+NET+The+ratios+of+measured+occupancy+ED(50)+values+(doses+at+which+50%25+occupancy+occurs)+among+SERT,+NET+and+DAT+sites+for+duloxetine,+venlafaxine,+nomifensine,+indatraline,+DOV+21,947+and+DOV+216,303+were+consistent+with+the+ratios+of+the+in+vitro+affinities+between+these+target+binding+sites+SERT+and+NET+occupancy+by+venlafaxine+and+milnacipran+in+nonhuman+primates:+a+PET+study+In+this+study+in+nonhuman+primates,+we+aimed+to+investigate+the+relationship+between+SERT+and+NET+affinity+by+measuring+the+in+vivo+occupancy+at+both+transporters+of+venlafaxine+and+milnacipran+We+hypothesized+that+venlafaxine+would+affect+monoamine+transporters+dose-dependently,+with+low+doses+causing+selective+reduction+of+SERT+binding+sites+and+higher+doses+reducing+both+SERT+and+NET+binding+sites+Comparative+studies+with+clinically+used+antidepressants+showed+that+venlafaxine+possessed+a+profile+similar+to+S33005+but+was+less+potent.+Clomipramine+likewise+interacted+with+SERTs+and+NETs+but+also+with+several+other+receptors+types,+while+citalopram+and+reboxetine+were+preferential+ligands+of+SERTs+and+NETs,+respectively.+In+conclusion,+S33005+interacts+potently+with+SERTs+and,+less+markedly,+with+NETs.++Venlafaxine+blocks+both+serotonin+and+norepinephrine+transporters+(SERT+and+NET),+with+higher+affinity+for+SERT.+Serotonergic+effects+occur+with+lower+doses,+whereas+both+serotonergic+and+noradrenergic+effects+occur+with+higher+doses+of+venlafaxine.+Taken+together,+the+results+from+this+study+indicate+that+the+low+dose+of+venlafaxine+blocked+selectively+the+reuptake+of+5-HT,+whereas+the+high+dose+blocked+the+reuptake+of+both+5-HT+and+NE.+Moreover,+an+enhancement+of+serotonergic+neurotransmission+by+venlafaxine+was+only+achieved+under+conditions+whereby+the+desensitization+of+the+terminal+5-HT(1B)+autoreceptor+is+appended+to+that+of+the+somatodendritic+5-HT(1A)+receptor.&tl=zh-CN&sl=en (Caused by ProxyError('Cannot connect to proxy.', ConnectionResetError(104, 'Connection reset by peer'))) Treatment for 14 days with 70 mg/kg per day venlafaxine, which inhibits both the NET and SERT, or 10 mg/kg per day phenelzine, a monoamine oxidase inhibitor, produced antidepressant-like effects on behavior without altering NET or SERT expression. Venlafaxine blocks both serotonin and norepinephrine transporters (SERT and NET), with higher affinity for SERT. Chronic venlafaxine treatment affected SERT and NET binding differently from paroxetine or desipramine. Venlafaxine blocks both serotonin and norepinephrine transporters (SERT and NET), with higher affinity for SERT Paroxetine and venlafaxine are potent serotonin transporter (SERT) antagonists and weaker norepinephrine transporter (NET) antagonists Using a novel blood assay that estimates CNS transporter occupancy we estimated the relative SERT and NET occupancy of paroxetine and venlafaxine in human subjects to assess the relative magnitude of SERT and NET inhibition Treatment for 14 days with 70 mg/kg per day venlafaxine, which inhibits both the NET and SERT, or 10 mg/kg per day phenelzine, a monoamine oxidase inhibitor, produced antidepressant-like effects on behavior without altering NET or SERT expression We then performed the first reported investigation of epistasis between the SERT gene and norepinephrine transporter gene (SLC6A2, alias NET) in AN, as an earlier study suggested that atypical AN responds to the dual serotonin-norepinephrine reuptake inhibitor venlafaxine Of particular interest were the findings that paroxetine, generally thought of as a selective SERT antagonist, possesses moderately high affinity for the NET and that venlafaxine, which has been described as a &quot;dual uptake inhibitor&quot;, possesses weak affinity for the NET The ratios of measured occupancy ED(50) values (doses at which 50% occupancy occurs) among SERT, NET and DAT sites for duloxetine, venlafaxine, nomifensine, indatraline, DOV 21,947 and DOV 216,303 were consistent with the ratios of the in vitro affinities between these target binding sites SERT and NET occupancy by venlafaxine and milnacipran in nonhuman primates: a PET study In this study in nonhuman primates, we aimed to investigate the relationship between SERT and NET affinity by measuring the in vivo occupancy at both transporters of venlafaxine and milnacipran We hypothesized that venlafaxine would affect monoamine transporters dose-dependently, with low doses causing selective reduction of SERT binding sites and higher doses reducing both SERT and NET binding sites Comparative studies with clinically used antidepressants showed that venlafaxine possessed a profile similar to S33005 but was less potent. Clomipramine likewise interacted with SERTs and NETs but also with several other receptors types, while citalopram and reboxetine were preferential ligands of SERTs and NETs, respectively. In conclusion, S33005 interacts potently with SERTs and, less markedly, with NETs.  Venlafaxine blocks both serotonin and norepinephrine transporters (SERT and NET), with higher affinity for SERT. Serotonergic effects occur with lower doses, whereas both serotonergic and noradrenergic effects occur with higher doses of venlafaxine. Taken together, the results from this study indicate that the low dose of venlafaxine blocked selectively the reuptake of 5-HT, whereas the high dose blocked the reuptake of both 5-HT and NE. Moreover, an enhancement of serotonergic neurotransmission by venlafaxine was only achieved under conditions whereby the desensitization of the terminal 5-HT(1B) autoreceptor is appended to that of the somatodendritic 5-HT(1A) receptor.
HTTPSConnectionPool(host='translate.google.com', port=443): Max retries exceeded with url: /m?q=Can+exosomes+be+detected+in+urine?&tl=zh-CN&sl=en (Caused by SSLError(SSLEOFError(8, 'EOF occurred in violation of protocol (_ssl.c:1131)'))) Can exosomes be detected in urine?
HTTPSConnectionPool(host='translate.google.com', port=443): Max retries exceeded with url: /m?q=Does+cortical+spreading+depression+appear+in+ischemic+penumbra+following+ischemic+stroke?&tl=zh-CN&sl=en (Caused by SSLError(SSLEOFError(8, 'EOF occurred in violation of protocol (_ssl.c:1131)'))) Does cortical spreading depression appear in ischemic penumbra following ischemic stroke?
HTTPSConnectionPool(host='translate.google.com', port=443): Max retries exceeded with url: /m?q=Since+this+region+partially+overlaps+with+residues+previously+implicated+in+block+of+the+channel+by+omega-conotoxin+GVIA,+we+assessed+the+effects+of+mutations+in+the+putative+EF+hand+domain+on+channel+block+by+omega-conotoxin+GVIA+and+the+structurally+related+omega-conotoxin+MVIIA.+Both+of+the+toxins+irreversibly+block+the+activity+of+wild+type+alpha(1B)+N-type+channels.++Despite+their+high+sequence+homology,+the+peptide+neurotoxins+omega-conotoxin+MVIIA+and+MVIIC+selectively+block+N-+and+P/Q-type+calcium+channels,+respectively.+++Binding+assay+for+both+N-+and+P/Q-type+calcium+channels+showed+that+amino+acid+residues+restricted+to+the+N-terminal+half+are+important+for+the+recognition+of+N-type+channels,+whereas+essential+residues+for+P/Q-type+channel+recognition+are+widely+spread+over+the+whole+omega-conotoxin+molecule.+Ziconotide+is+a+novel+peptide+that+blocks+the+entry+of+calcium+into+neuronal+N-type+voltage-sensitive+calcium+channels,+preventing+the+conduction+of+nerve+signals.+Ziconotide+is+a+selective,+potent+and+reversible+blocker+of+neuronal+N-type+voltage-sensitive+calcium+channels+(VSCCs).+The+therapeutic+benefit+of+ziconotide+derives+from+its+potent+and+selective+blockade+of+neuronal+N-type+voltage-sensitive+calcium+channels.+Interactions+of+intrathecally+administered+ziconotide,+a+selective+blocker+of+neuronal+N-type+voltage-sensitive+calcium+channels,+with+morphine+on+nociception+in+rats.+Ziconotide,+a+new+N-type+calcium+channel+blocker,+administered+intrathecally+for+acute+postoperative+pain.+Ziconotide,+an+intrathecally+administered+N-type+calcium+channel+antagonist+for+the+treatment+of+chronic+pain.+Thus,+ziconotide+is+the+first+of+a+new+class+of+agents--N-type+calcium+channel+blockers,+or+NCCBs.+Ziconotide,+formerly+known+also+as+SNX-+111,+represents+a+new+class+of+agents,+the+N-type+calcium+channel+blockers.+The+selective+N-type+calcium+channel+blocker+ziconotide+ameliorates+severe+chronic+pain+but+has+a+narrow+therapeutic+window+and+requires+intrathecal+administration.+A+selective+N-type+calcium+channel+inhibitor,+ziconotide+(Prialt),+is+a+neuroactive+peptide+recently+marketed+as+a+novel+nonopioid+treatment+for+severe+chronic+pain.+As+the+clinically+available+analgesics,+pregabalin+(alpha2delta-subunit+calcium+channel+ligand),+ziconotide+(N-type+calcium+channel+blocker),+mexiletine+(sodium+channel+blocker),+and+duloxetine+(serotonin+and+norepinephrine+reuptake+inhibitors)+were+evaluated+in+these+neurochemically-induced+allodynia+models.+The+present+investigation+was+designed+to+assess+the+safety+and+analgesic+efficacy+of+ziconotide,+a+new+N-type+calcium+channel+blocker,+when+administered+intrathecally+to+patients+with+acute+postoperative+pain.+Inhibition+of+the+N-type+calcium+channel+by+intrathecal+administration+of+the+channel-specific+blocker+omega-conotoxin+MVIIA+(ziconotide)+is+efficacious+in+the+treatment+of+severe+chronic+pain.+Ziconotide+is+a+powerful+analgesic+drug+that+has+a+unique+mechanism+of+action+involving+potent+and+selective+block+of+N-type+calcium+channels,+which+control+neurotransmission+at+many+synapses.+In+conclusion,+present+findings+provide+implication+that+the+spinal+anti-nociceptive+mechanistic+site+of+pregabalin+is+different+from+that+of+ziconotide,+mexiletine,+and+duloxetine,+and+pregabalin+could+have+a+broader+anti-nociceptive+mechanism+other+than+N-type+calcium+channel+blockade.+Ziconotide+(SNX-111),+a+selective+blocker+of+neuronal+N-type+voltage-sensitive+calcium+channels,+is+antinociceptive+when+it+is+administered+intrathecally.+Effects+of+intrathecal+administration+of+ziconotide,+a+selective+neuronal+N-type+calcium+channel+blocker,+on+mechanical+allodynia+and+heat+hyperalgesia+in+a+rat+model+of+postoperative+pain.+A+state-dependent+Ca(V)2.2+inhibitor+may+provide+an+improved+therapeutic+window+over+ziconotide,+the+peptidyl+Ca(V)2.2+inhibitor+used+clinically.++There+is+also+human+validation+data+from+ziconotide,+the+CaV2.2-selective+peptidyl+inhibitor+used+clinically+to+treat+refractory+pain.++A+selective+N-type+calcium+channel+inhibitor,+ziconotide+(Prialt),+is+a+neuroactive+peptide+recently+marketed+as+a+novel+nonopioid+treatment+for+severe+chronic+pain.++The+neuroprotective+effects+of+intrathecal+administration+of+the+selective+N-type+calcium+channel+blocker+ziconotide+in+a+rat+model+of+spinal+ischemia.&tl=zh-CN&sl=en (Caused by ProxyError('Cannot connect to proxy.', ConnectionResetError(104, 'Connection reset by peer'))) ./train.json: 141it [11:27,  4.98s/it]./train.json: 142it [11:33,  5.32s/it]./train.json: 143it [11:38,  5.25s/it]./train.json: 144it [11:43,  5.12s/it]./train.json: 145it [11:49,  5.40s/it]./train.json: 146it [11:55,  5.74s/it]./train.json: 147it [12:00,  5.46s/it]./train.json: 148it [12:03,  4.76s/it]./train.json: 149it [12:06,  4.16s/it]./train.json: 150it [12:09,  3.83s/it]./train.json: 151it [12:12,  3.68s/it]./train.json: 152it [12:15,  3.27s/it]./train.json: 153it [12:19,  3.55s/it]./train.json: 154it [12:24,  4.08s/it]./train.json: 155it [12:28,  4.07s/it]./train.json: 156it [12:32,  4.10s/it]./train.json: 157it [12:37,  4.29s/it]./train.json: 158it [12:41,  4.29s/it]./train.json: 159it [12:46,  4.26s/it]./train.json: 160it [12:51,  4.45s/it]./train.json: 161it [12:56,  4.67s/it]./train.json: 162it [13:01,  4.88s/it]./train.json: 163it [13:05,  4.73s/it]./train.json: 164it [13:11,  4.93s/it]./train.json: 165it [13:15,  4.78s/it]./train.json: 166it [13:20,  4.79s/it]./train.json: 167it [13:26,  5.15s/it]./train.json: 168it [13:32,  5.38s/it]./train.json: 169it [13:36,  4.88s/it]./train.json: 170it [13:42,  5.24s/it]./train.json: 171it [13:45,  4.72s/it]./train.json: 172it [13:51,  4.94s/it]./train.json: 173it [13:56,  5.01s/it]./train.json: 174it [14:00,  4.79s/it]./train.json: 175it [14:05,  4.70s/it]./train.json: 176it [14:10,  4.85s/it]./train.json: 177it [14:14,  4.61s/it]./train.json: 178it [14:18,  4.42s/it]./train.json: 179it [14:23,  4.77s/it]./train.json: 180it [14:28,  4.62s/it]./train.json: 181it [14:32,  4.49s/it]./train.json: 182it [14:36,  4.36s/it]./train.json: 183it [14:40,  4.24s/it]./train.json: 184it [14:44,  4.32s/it]./train.json: 185it [14:49,  4.28s/it]./train.json: 186it [14:55,  4.78s/it]./train.json: 187it [15:01,  5.26s/it]./train.json: 188it [15:06,  5.08s/it]./train.json: 189it [15:09,  4.58s/it]./train.json: 190it [15:13,  4.42s/it]./train.json: 191it [15:20,  5.15s/it]./train.json: 192it [15:23,  4.60s/it]./train.json: 193it [15:27,  4.28s/it]./train.json: 194it [15:31,  4.13s/it]./train.json: 195it [15:35,  4.08s/it]./train.json: 196it [15:38,  3.99s/it]./train.json: 197it [15:43,  4.06s/it]./train.json: 198it [15:47,  4.11s/it]./train.json: 199it [15:51,  4.12s/it]./train.json: 200it [15:55,  3.97s/it]./train.json: 201it [15:58,  3.80s/it]./train.json: 202it [16:01,  3.69s/it]./train.json: 203it [16:05,  3.64s/it]./train.json: 204it [16:09,  3.71s/it]./train.json: 205it [16:13,  3.82s/it]./train.json: 206it [16:16,  3.74s/it]./train.json: 207it [16:20,  3.65s/it]./train.json: 208it [16:24,  3.78s/it]./train.json: 209it [16:27,  3.64s/it]./train.json: 210it [16:32,  3.93s/it]./train.json: 211it [16:36,  3.94s/it]./train.json: 212it [16:41,  4.29s/it]./train.json: 213it [16:45,  4.14s/it]./train.json: 214it [16:49,  4.09s/it]./train.json: 215it [16:53,  4.06s/it]./train.json: 216it [16:56,  3.85s/it]Since this region partially overlaps with residues previously implicated in block of the channel by omega-conotoxin GVIA, we assessed the effects of mutations in the putative EF hand domain on channel block by omega-conotoxin GVIA and the structurally related omega-conotoxin MVIIA. Both of the toxins irreversibly block the activity of wild type alpha(1B) N-type channels.  Despite their high sequence homology, the peptide neurotoxins omega-conotoxin MVIIA and MVIIC selectively block N- and P/Q-type calcium channels, respectively.   Binding assay for both N- and P/Q-type calcium channels showed that amino acid residues restricted to the N-terminal half are important for the recognition of N-type channels, whereas essential residues for P/Q-type channel recognition are widely spread over the whole omega-conotoxin molecule. Ziconotide is a novel peptide that blocks the entry of calcium into neuronal N-type voltage-sensitive calcium channels, preventing the conduction of nerve signals. Ziconotide is a selective, potent and reversible blocker of neuronal N-type voltage-sensitive calcium channels (VSCCs). The therapeutic benefit of ziconotide derives from its potent and selective blockade of neuronal N-type voltage-sensitive calcium channels. Interactions of intrathecally administered ziconotide, a selective blocker of neuronal N-type voltage-sensitive calcium channels, with morphine on nociception in rats. Ziconotide, a new N-type calcium channel blocker, administered intrathecally for acute postoperative pain. Ziconotide, an intrathecally administered N-type calcium channel antagonist for the treatment of chronic pain. Thus, ziconotide is the first of a new class of agents--N-type calcium channel blockers, or NCCBs. Ziconotide, formerly known also as SNX- 111, represents a new class of agents, the N-type calcium channel blockers. The selective N-type calcium channel blocker ziconotide ameliorates severe chronic pain but has a narrow therapeutic window and requires intrathecal administration. A selective N-type calcium channel inhibitor, ziconotide (Prialt), is a neuroactive peptide recently marketed as a novel nonopioid treatment for severe chronic pain. As the clinically available analgesics, pregabalin (alpha2delta-subunit calcium channel ligand), ziconotide (N-type calcium channel blocker), mexiletine (sodium channel blocker), and duloxetine (serotonin and norepinephrine reuptake inhibitors) were evaluated in these neurochemically-induced allodynia models. The present investigation was designed to assess the safety and analgesic efficacy of ziconotide, a new N-type calcium channel blocker, when administered intrathecally to patients with acute postoperative pain. Inhibition of the N-type calcium channel by intrathecal administration of the channel-specific blocker omega-conotoxin MVIIA (ziconotide) is efficacious in the treatment of severe chronic pain. Ziconotide is a powerful analgesic drug that has a unique mechanism of action involving potent and selective block of N-type calcium channels, which control neurotransmission at many synapses. In conclusion, present findings provide implication that the spinal anti-nociceptive mechanistic site of pregabalin is different from that of ziconotide, mexiletine, and duloxetine, and pregabalin could have a broader anti-nociceptive mechanism other than N-type calcium channel blockade. Ziconotide (SNX-111), a selective blocker of neuronal N-type voltage-sensitive calcium channels, is antinociceptive when it is administered intrathecally. Effects of intrathecal administration of ziconotide, a selective neuronal N-type calcium channel blocker, on mechanical allodynia and heat hyperalgesia in a rat model of postoperative pain. A state-dependent Ca(V)2.2 inhibitor may provide an improved therapeutic window over ziconotide, the peptidyl Ca(V)2.2 inhibitor used clinically.  There is also human validation data from ziconotide, the CaV2.2-selective peptidyl inhibitor used clinically to treat refractory pain.  A selective N-type calcium channel inhibitor, ziconotide (Prialt), is a neuroactive peptide recently marketed as a novel nonopioid treatment for severe chronic pain.  The neuroprotective effects of intrathecal administration of the selective N-type calcium channel blocker ziconotide in a rat model of spinal ischemia.
HTTPSConnectionPool(host='translate.google.com', port=443): Max retries exceeded with url: /m?q=Is+Calcium+homeostasis+important+in+cardiac+physiology+and+pathophysiology?&tl=zh-CN&sl=en (Caused by ProxyError('Cannot connect to proxy.', ConnectionResetError(104, 'Connection reset by peer'))) Is Calcium homeostasis important in cardiac physiology and pathophysiology?
HTTPSConnectionPool(host='translate.google.com', port=443): Max retries exceeded with url: /m?q=Has+the+fungus+Ashbya+gossypii+got+many+nuclei+that+share+cytoplasm?&tl=zh-CN&sl=en (Caused by ProxyError('Cannot connect to proxy.', ConnectionResetError(104, 'Connection reset by peer'))) Has the fungus Ashbya gossypii got many nuclei that share cytoplasm?
("Connection broken: InvalidChunkLength(got length b'', 0 bytes read)", InvalidChunkLength(got length b'', 0 bytes read)) ./train.json: 217it [17:00,  3.78s/it]./train.json: 218it [17:03,  3.67s/it]./train.json: 219it [17:07,  3.78s/it]./train.json: 220it [17:11,  3.77s/it]./train.json: 221it [17:14,  3.56s/it]JNJ-26481585 also fully inhibited the growth of C170HM2 colorectal liver metastases, whereas again 5-fluorouracil/Leucovorin showed modest activity. Although not meeting the RECIST response criteria for adequate single-agent activity, the observed tolerable toxicities and the potential for clinical benefit in terms of stable disease suggest that further assessment of vorinostat as a part of combination therapy with either chemotherapeutic or targeted agents in metastatic breast might be undertaken. Treatments of different structural classes of HDACi simultaneously induced cell death and promoted cell migration and metastasis in multiple cancer cell types. Suppression of HDACi-induced PKCs leads to development of low toxic and long-term therapeutic strategies to potentially treat cancer as a chronic disease. mRNA expression analysis of lung tumor bearing mice suggested that the enhanced chemopreventive activity of the combination is related to atorvastatin modulation of DNA repair, SAHA modulation of angiogenesis, and both drugs modulating invasion and metastasis pathways. Histone deacetylase (HDAC) inhibitors induced morphologic differentiation, cell-cycle exit, and a shift to a differentiated, melanocytic gene expression profile in cultured UM cells. VPA inhibited the growth of UM tumors in vivo. When both drugs were used in concert additive effects were observed on the migratory and invasive behavior but not on tumor-endothelium and tumor-matrix interaction. Separate mTOR or HDAC inhibition slows processes related to tumor metastasis. The RAD001-VPA combination showed advantage over VPA monotreatment with particular respect to migration and invasion. In conclusion, sequential treatments of mice with MS-275 followed by TRAIL may target multiple pathways to reverse EMT and inhibit tumor progression, angiogenesis, and metastasis and represent a novel therapeutic approach to treat cancer. In vivo, AA98 synergized with vorinostat to inhibit tumor growth and metastasis. We report the first preclinical data for the prevention of brain metastasis of triple-negative breast cancer. Vorinostat is brain permeable and can prevent the formation of brain metastases by 62%. Its mechanism of action involves the induction of DNA double-strand breaks, suggesting rational combinations with DNA active drugs or radiation. Combining vorinostat with radiation may be a potential treatment option for patients with breast cancer who develop brain metastases. Although single-agent PCI-24781 had modest effects on STS growth and metastasis, marked inhibition was observed when combined with chemotherapy. In a 4T1 metastatic breast carcinoma model, AN-7 inhibited the formation of lung lesions by 76% and AN-9 by 47%, further demonstrating the greater efficacy of AN-7 compared to AN-9 (P<0.02). Both AN-7 and AN-9 exhibited antimetastatic and antiangiogenic activities by reducing vascularization, bFGF expression and HIF-1alpha. Since prolonged oral administration with 50 mg/kg or a single oral dose of 1.2 g/kg AN-7 did not cause adverse effects and the former exhibited significant anticancer activity, AN-7 is likely to display a high therapeutic index and may be beneficial for prostate cancer patients. We show that apicidin significantly inhibits H-ras-induced invasive phenotype of MCF10A human breast epithelial cells in parallel with a specific downregulation of matrix metalloproteinase (MMP)-2, but not MMP-9. We also show that apicidin induces a morphological reversal and growth inhibition of H-ras MCF10A cells similar to that induced by other HDAC inhibitors. We also found that NaB induced three genes, which are known metastatic suppressors, and downregulated 11 genes, which have been shown to promote metastasis.
HTTPSConnectionPool(host='translate.google.com', port=443): Max retries exceeded with url: /m?q=Inherited+mutations+in+genes+involved+in+HR+are+associated+with+gene+rearrangement+and+may+be+a+prerequisite+for+tumor+development+in+some+cancer-prone+hereditary+diseases+like+Bloom,+Werner+and+Rothmund-Thomson+syndromes.++Variants+in+the+XRCC3+gene+might+result+in+altered+protein+structure+or+function+which+may+influence+DSBR+efficiency+and+lead+to+cancer.++Although+alcohol+consumption+is+related+to+increased+cancer+risk,+its+molecular+mechanism+remains+unclear.+Here,+we+demonstrate+that+an+intake+of+10%25+alcohol+for+4+weeks+in+rats+is+genotoxic+due+to+induction+of+micronuclei.+Acetaldehyde+(AA),+the+first+product+of+ethanol+metabolism,+is+believed+to+be+responsible+for+DNA+damage+induced+by+alcohol.++Although+efficiency+of+these+repair+processes+substantially+decrease+the+efficacy+of+cancer+chemotherapies+that+target+DNA,+compromised+DNA+repair+contributes+to+mutagenesis+and+genomic+instability+leading+to+carcinogenesis.+damage+response+and+repair+pathways+are+important+barriers+to+carcinogenesis.++olymorphisms+in+DNA+repair+genes+and+differences+in+repair+capacity+between+individuals+have+been+widely+documented.+For+colorectal+cancer,+the+loss+of+mismatch+repair+gene+activity+is+a+key+genetic+determinant.+Nucleotide+excision+repair+(NER),+recombination+repair+(RR)+and+base+excision+repair+(BER)+pathways+have+critical+roles+in+protection+against+other+cancers,+and+we+wished+to+investigate+their+role+in+colorectal+cancer.&tl=zh-CN&sl=en (Caused by SSLError(SSLEOFError(8, 'EOF occurred in violation of protocol (_ssl.c:1131)'))) Inherited mutations in genes involved in HR are associated with gene rearrangement and may be a prerequisite for tumor development in some cancer-prone hereditary diseases like Bloom, Werner and Rothmund-Thomson syndromes.  Variants in the XRCC3 gene might result in altered protein structure or function which may influence DSBR efficiency and lead to cancer.  Although alcohol consumption is related to increased cancer risk, its molecular mechanism remains unclear. Here, we demonstrate that an intake of 10% alcohol for 4 weeks in rats is genotoxic due to induction of micronuclei. Acetaldehyde (AA), the first product of ethanol metabolism, is believed to be responsible for DNA damage induced by alcohol.  Although efficiency of these repair processes substantially decrease the efficacy of cancer chemotherapies that target DNA, compromised DNA repair contributes to mutagenesis and genomic instability leading to carcinogenesis. damage response and repair pathways are important barriers to carcinogenesis.  olymorphisms in DNA repair genes and differences in repair capacity between individuals have been widely documented. For colorectal cancer, the loss of mismatch repair gene activity is a key genetic determinant. Nucleotide excision repair (NER), recombination repair (RR) and base excision repair (BER) pathways have critical roles in protection against other cancers, and we wished to investigate their role in colorectal cancer.
./train.json: 222it [17:17,  3.28s/it]./train.json: 223it [17:21,  3.56s/it]./train.json: 224it [17:23,  3.24s/it]HTTPSConnectionPool(host='translate.google.com', port=443): Max retries exceeded with url: /m?q=High-dose+glucocorticoid+therapy+in+the+management+of+seizures+in+neonatal+incontinentia+pigmenti+Incontinentia+pigmenti+is+an+X-linked+dominant+disorder+resulting+from+a+mutation+of+IKBKG.+This+disorder+has+a+classic+dermatologic+presentation,+but+neurologic+involvement,+with+seizures+and+cortical+infarction,+can+arise+shortly+after+birth+Some+children+with+incontinentia+pigmenti+exhibit+encephalopathic+features+with+severe+seizures+and+disturbed+consciousness,+from+the+neonatal+through+the+early+infantile+period+Incontinentia+pigmenti+(IP)+is+a+rare+X-linked+dominant+neurocutaneous+disorder+affecting+ectodermal+tissue:+skin,+eyes,+central+nervous+system,+hair,+nails,+and+teeth.+It+is+usually+lethal+for+males+in+utero.+The+involved+gene+is+NEMO,+an+essential+component+of+the+nuclear+factor-kappa+B+(NF-%CE%BAB)+signaling+pathway.+Skin+lesions+are+highly+diagnostic,+occurring+in+neonates,+with+a+particular+distribution+on+Blaschko+lines.+The+severity+of+the+disease+is+related+to+ocular+and+neurological+impairment.+The+hallmark+of+ocular+IP+is+retinal+vasculopathy+including+peripheral+retinal+vascular+nonperfusion,+macular+infarction+and+neovascularization,+and+preretinal+neovascularization.+CNS+involvement+consists+of+seizures,+mental+retardation,+hemiparesis,+spasticity,+microcephaly,+cerebellar+ataxia,+and+coma+Incontinentia+Pigmenti+is+a+rare+X-linked+multisystem+disorder+with+well+described+and+pathognomonic+skin+manifestations.+Neurological+manifestations+are+found+in+30%25+of+IP+patients,+forming+one+of+the+major+causes+of+morbidity+and+mortality+of+the+condition.+In+this+review,+clinical+and+brain+imaging+data+of+45+IP+patients+with+a+neurological+phenotype+are+reviewed.+Several+clinical+presentations+could+be+identified,+comprising+seizures,+infantile+encephalopathy,+acute+disseminated+encephalomyelitis+and+ischemic+stroke+Incontinentia+pigmenti+presenting+as+seizures.+Neonatal+seizures+in+two+sisters+with+incontinentia+pigmenti.+High-dose+glucocorticoid+therapy+in+the+management+of+seizures+in+neonatal+incontinentia+pigmenti:+a+case+report.+Incontinentia+Pigmenti+is+an+X-linked+dominant+neurocutaneous+disorder+with+central+nervous+system+manifestations+in+30%25+of+cases,+including+seizures+and+mental+retardation.+Neonatal+seizures+in+two+sisters+with+incontinentia+pigmenti+A+rare+cause+of+neonatal+seizure:+incontinentia+pigmenti.+Here,+we+describe+the+clinical,+electrographic,+and+neuroradiologic+effect+of+systemic+glucocorticoid+therapy+in+a+neonate+with+incontinentia+pigmenti+manifesting+an+epileptic+encephalopathy.+Incontinentia+pigmenti+presenting+as+seizures.+Neonatal+seizures+in+two+sisters+with+incontinentia+pigmenti.&tl=zh-CN&sl=en (Caused by SSLError(SSLEOFError(8, 'EOF occurred in violation of protocol (_ssl.c:1131)'))) High-dose glucocorticoid therapy in the management of seizures in neonatal incontinentia pigmenti Incontinentia pigmenti is an X-linked dominant disorder resulting from a mutation of IKBKG. This disorder has a classic dermatologic presentation, but neurologic involvement, with seizures and cortical infarction, can arise shortly after birth Some children with incontinentia pigmenti exhibit encephalopathic features with severe seizures and disturbed consciousness, from the neonatal through the early infantile period Incontinentia pigmenti (IP) is a rare X-linked dominant neurocutaneous disorder affecting ectodermal tissue: skin, eyes, central nervous system, hair, nails, and teeth. It is usually lethal for males in utero. The involved gene is NEMO, an essential component of the nuclear factor-kappa B (NF-B) signaling pathway. Skin lesions are highly diagnostic, occurring in neonates, with a particular distribution on Blaschko lines. The severity of the disease is related to ocular and neurological impairment. The hallmark of ocular IP is retinal vasculopathy including peripheral retinal vascular nonperfusion, macular infarction and neovascularization, and preretinal neovascularization. CNS involvement consists of seizures, mental retardation, hemiparesis, spasticity, microcephaly, cerebellar ataxia, and coma Incontinentia Pigmenti is a rare X-linked multisystem disorder with well described and pathognomonic skin manifestations. Neurological manifestations are found in 30% of IP patients, forming one of the major causes of morbidity and mortality of the condition. In this review, clinical and brain imaging data of 45 IP patients with a neurological phenotype are reviewed. Several clinical presentations could be identified, comprising seizures, infantile encephalopathy, acute disseminated encephalomyelitis and ischemic stroke Incontinentia pigmenti presenting as seizures. Neonatal seizures in two sisters with incontinentia pigmenti. High-dose glucocorticoid therapy in the management of seizures in neonatal incontinentia pigmenti: a case report. Incontinentia Pigmenti is an X-linked dominant neurocutaneous disorder with central nervous system manifestations in 30% of cases, including seizures and mental retardation. Neonatal seizures in two sisters with incontinentia pigmenti A rare cause of neonatal seizure: incontinentia pigmenti. Here, we describe the clinical, electrographic, and neuroradiologic effect of systemic glucocorticoid therapy in a neonate with incontinentia pigmenti manifesting an epileptic encephalopathy. Incontinentia pigmenti presenting as seizures. Neonatal seizures in two sisters with incontinentia pigmenti.
HTTPSConnectionPool(host='translate.google.com', port=443): Max retries exceeded with url: /m?q=Genome-wide+analysis+of+fragile+sites+by+chromatin+immunoprecipitation+(ChIP)+and+microarray+(ChIP-chip)+of+phosphorylated+H2A+in+these+mutants+supported+a+transcription-dependent+mechanism+of+DNA+damage+characteristic+of+R+loops+We+have+used+a+bisulfite-sensitivity+assay+to+demonstrate+genome-wide+increase+in+the+occurrence+of+RNA-DNA+hybrids+(R-loops),+including+from+antisense+and+read-through+transcripts,+in+a+nusG+missense+mutant+defective+for+Rho-dependent+termination.+The+results+demonstrate+a+key+function+of+FACT+in+the+resolution+of+R-loop-mediated+transcription-replication+conflicts,+likely+associated+with+a+specific+chromatin+organization.+Previous+work+revealed+that+GC+skew+and+R-loop+formation+associate+with+a+core+set+of+unmethylated+CpG+island+(CGI)+promoters+in+the+human+genome&tl=zh-CN&sl=en (Caused by SSLError(SSLEOFError(8, 'EOF occurred in violation of protocol (_ssl.c:1131)'))) Genome-wide analysis of fragile sites by chromatin immunoprecipitation (ChIP) and microarray (ChIP-chip) of phosphorylated H2A in these mutants supported a transcription-dependent mechanism of DNA damage characteristic of R loops We have used a bisulfite-sensitivity assay to demonstrate genome-wide increase in the occurrence of RNA-DNA hybrids (R-loops), including from antisense and read-through transcripts, in a nusG missense mutant defective for Rho-dependent termination. The results demonstrate a key function of FACT in the resolution of R-loop-mediated transcription-replication conflicts, likely associated with a specific chromatin organization. Previous work revealed that GC skew and R-loop formation associate with a core set of unmethylated CpG island (CGI) promoters in the human genome
./train.json: 225it [17:26,  3.06s/it]./train.json: 226it [17:29,  2.95s/it]HTTPSConnectionPool(host='translate.google.com', port=443): Max retries exceeded with url: /m?q=These+mutations+were+frequent+in+plasmid-borne+lacS+expressed+at+a+high+level+but+not+in+single-copy+lacS+in+the+chromosome+or+at+lower+levels+of+expression+in+a+plasmid.+The+results+suggest+that+important+DNA+repair+or+replication+fidelity+functions+are+impaired+or+overwhelmed+in+pJlacS,+with+results+analogous+to+those+of+the+%22transcription-associated+mutagenesis%22+seen+in+bacteria+and+eukaryotes.+the+rate+of+point+mutation+in+a+gene+increases+with+the+expression+level+of+the+gene.+Transcription+induces+mutagenesis+on+both+DNA+strands,+indicating+simultaneous+actions+of+several+TAM+mechanisms.+High-levels+of+transcription+through+a+gene+stimulate+spontaneous+mutation+rate,+a+phenomenon+termed+transcription-associated+mutation+(TAM).+High+levels+of+transcription+in+Saccharomyces+cerevisiae+are+associated+with+increased+genetic+instability,+which+has+been+linked+to+DNA+damage.+Here,+we+describe+a+pGAL-CAN1+forward+mutation+assay+for+studying+transcription-associated+mutagenesis+(TAM)+in+yeast.+The+acquisition+of+mutations+was+directly+correlated+to+the+level+of+transcription+Our+results+demonstrate+that+the+level+of+Leu(%2B)+reversions+increased+significantly+in+parallel+with+the+induced+increase+in+transcription+levels.+Transcription-associated+mutagenesis+in+yeast+is+directly+proportional+to+the+level+of+gene+expression+spontaneous+mutation+rate+is+directly+proportional+to+the+transcription+level,+suggesting+that+movement+of+RNA+polymerase+through+the+target+initiates+a+mutagenic+process(es)+High+transcription+is+associated+with+genetic+instability,+notably+increased+spontaneous+mutation+rates,+which+is+a+phenomenon+termed+Transcription-Associated-Mutagenesis+(TAM).+Using+this+system,+we+also+investigated+two+hypotheses+that+have+been+proposed+to+explain+transcription-associated+mutagenesis+(TAM):+(1)+transcription+impairs+replication+fork+progression+in+a+directional+manner+and+(2)+DNA+lesions+accumulate+under+high-transcription+conditions.+Transcription-associated+mutagenesis+in+yeast+is+directly+proportional+to+the+level+of+gene+expression+and+influenced+by+the+direction+of+DNA+replication.+High+levels+of+transcription+in+Saccharomyces+cerevisiae+are+associated+with+increased+genetic+instability,+which+has+been+linked+to+DNA+damage.+Using+this+system,+we+also+investigated+two+hypotheses+that+have+been+proposed+to+explain+transcription-associated+mutagenesis+(TAM):+(1)+transcription+impairs+replication+fork+progression+in+a+directional+manner+and+(2)+DNA+lesions+accumulate+under+high-transcription+conditions.+Using+comparative+genomics+of+related+species+as+well+as+mutation+accumulation+lines,+we+show+in+yeast+that+the+rate+of+point+mutation+in+a+gene+increases+with+the+expression+level+of+the+gene+High+transcription+is+associated+with+genetic+instability,+notably+increased+spontaneous+mutation+rates,+which+is+a+phenomenon+termed+Transcription-Associated-Mutagenesis+(TAM)+Using+this+system,+we+also+investigated+two+hypotheses+that+have+been+proposed+to+explain+transcription-associated+mutagenesis+(TAM):+(1)+transcription+impairs+replication+fork+progression+in+a+directional+manner+and+(2)+DNA+lesions+accumulate+under+high-transcription+conditions+High-levels+of+transcription+through+a+gene+stimulate+spontaneous+mutation+rate,+a+phenomenon+termed+transcription-associated+mutation+(TAM)&tl=zh-CN&sl=en (Caused by SSLError(SSLEOFError(8, 'EOF occurred in violation of protocol (_ssl.c:1131)'))) These mutations were frequent in plasmid-borne lacS expressed at a high level but not in single-copy lacS in the chromosome or at lower levels of expression in a plasmid. The results suggest that important DNA repair or replication fidelity functions are impaired or overwhelmed in pJlacS, with results analogous to those of the "transcription-associated mutagenesis" seen in bacteria and eukaryotes. the rate of point mutation in a gene increases with the expression level of the gene. Transcription induces mutagenesis on both DNA strands, indicating simultaneous actions of several TAM mechanisms. High-levels of transcription through a gene stimulate spontaneous mutation rate, a phenomenon termed transcription-associated mutation (TAM). High levels of transcription in Saccharomyces cerevisiae are associated with increased genetic instability, which has been linked to DNA damage. Here, we describe a pGAL-CAN1 forward mutation assay for studying transcription-associated mutagenesis (TAM) in yeast. The acquisition of mutations was directly correlated to the level of transcription Our results demonstrate that the level of Leu(+) reversions increased significantly in parallel with the induced increase in transcription levels. Transcription-associated mutagenesis in yeast is directly proportional to the level of gene expression spontaneous mutation rate is directly proportional to the transcription level, suggesting that movement of RNA polymerase through the target initiates a mutagenic process(es) High transcription is associated with genetic instability, notably increased spontaneous mutation rates, which is a phenomenon termed Transcription-Associated-Mutagenesis (TAM). Using this system, we also investigated two hypotheses that have been proposed to explain transcription-associated mutagenesis (TAM): (1) transcription impairs replication fork progression in a directional manner and (2) DNA lesions accumulate under high-transcription conditions. Transcription-associated mutagenesis in yeast is directly proportional to the level of gene expression and influenced by the direction of DNA replication. High levels of transcription in Saccharomyces cerevisiae are associated with increased genetic instability, which has been linked to DNA damage. Using this system, we also investigated two hypotheses that have been proposed to explain transcription-associated mutagenesis (TAM): (1) transcription impairs replication fork progression in a directional manner and (2) DNA lesions accumulate under high-transcription conditions. Using comparative genomics of related species as well as mutation accumulation lines, we show in yeast that the rate of point mutation in a gene increases with the expression level of the gene High transcription is associated with genetic instability, notably increased spontaneous mutation rates, which is a phenomenon termed Transcription-Associated-Mutagenesis (TAM) Using this system, we also investigated two hypotheses that have been proposed to explain transcription-associated mutagenesis (TAM): (1) transcription impairs replication fork progression in a directional manner and (2) DNA lesions accumulate under high-transcription conditions High-levels of transcription through a gene stimulate spontaneous mutation rate, a phenomenon termed transcription-associated mutation (TAM)
HTTPSConnectionPool(host='translate.google.com', port=443): Max retries exceeded with url: /m?q=Is+there+a+pharmacogenetic+test+for+trastuzumab?&tl=zh-CN&sl=en (Caused by SSLError(SSLEOFError(8, 'EOF occurred in violation of protocol (_ssl.c:1131)'))) Is there a pharmacogenetic test for trastuzumab?
HTTPSConnectionPool(host='translate.google.com', port=443): Max retries exceeded with url: /m?q=At+recurrence,+treatment+options+include+repeat+surgery+(with+or+without+Gliadel+wafer+placement),+reirradiation+or+systemic+therapy.++DISCUSSION:+Carmustine+wafers+for+primary+HGG+surgery+in+accordance+with+the+NICE+TA121+were+associated+with+a+median+survival+of+15.3+months;+this+is+improved+compared+with+previously+reported+randomised+trials.+Multimodal+treatment+with+carmustine+wafers,+radical+radiotherapy+and+concomitant+temozolomide+was+associated+with+improved+survival.+Gliadel+wafer+is+a+new+approach+to+the+treatment+of+glioblastoma,+which+involves+controlled+release+delivery+of+carmustine+from+biodegradable+polymer+wafers.+It+has+shown+promising+results+and+provides+a+silver+lining+for+glioblastoma+patients.+For+patient+with+and+without+Gliadel,+median+and+1-year+RFS+were+12.9+months+and+52%25+vs.+14+months+and+42%25,+respectively+(p+%3D+0.89).+According+to+pathology,+Gliadel+did+not+influence+OS+of+patients+with+Grade+III+or+glioblastoma+CONCLUSION:+In+patients+with+high-grade+gliomas,+adding+Gliadel+before+performing+a+Stupp+protocol+did+not+improve+survival.+Randomized+phase+III+trials+have+shown+significant+improvement+of+survival+1,+2,+and+3+years+after+implantation+of+1,3-bis+(2-chloroethyl)-1-nitrosourea+(BCNU)+wafers+for+patients+with+newly+diagnosed+malignant+glioma.++CONCLUSIONS:+The+combination+of+aggressive+resection,+Gliadel+wafer+implantation,+and+GKS+in+addition+to+standard+fractionated+RT+in+selected+patients+resulted+in+increased+local+control+and+increased+survival+compared+with+a+historical+control+group+treated+with+surgery+and+involved-field+RT+alone.+OBJECT:+Gliadel+(BCNU)+wafer+and+concomitant+temozolomide+(TMZ)+therapy,+when+used+individually+as+adjuvant+therapies,+extend+survival+from+that+achieved+by+resection+and+radiation+therapy+(XRT)+for+glioblastoma+multiforme+(GBM).++BACKGROUND:+Gliadel+(polifeprosan+20+with+carmustine+%5BBCNU%5D+implant)+is+commonly+used+for+local+delivery+of+BCNU+to+high-grade+gliomas+after+resection+and+is+associated+with+increased+survival.+Temozolomide+administered+according+to+this+protocol+produced+a+median+survival+benefit+of+2+months+in+glioblastomas,+and+carmustine+a+similar+benefit+in+high-grade+gliomas.+Analysis+of+a+large+trial+by+Westphal+and+colleagues+(n+%3D+240)+showed+a+29%25+risk+reduction+(P+%3D+0.03)+in+the+BCNU+wafer-treated+group+over+the+course+of+the+30-month+trial.+Median+survival+of+patients+treated+with+BCNU+wafers+was+13.8+months+vs+11.6+months+in+placebo-treated+patients+(P+%3D+0.017)+with+a+hazard+ratio+of+0.73+(P+%3D+0.018),+representing+a+27%25+significant+risk+reduction.+This+survival+advantage+was+maintained+at+1,+2,+and+3+years+and+was+statistically+significant+(P+%3D+0.01)+at+3+years.+CONCLUSION:+Malignant+glioma+patients+treated+with+BCNU+wafers+at+the+time+of+initial+surgery+in+combination+with+radiation+therapy+demonstrated+a+survival+advantage+at+2+and+3+years+follow-up+compared+with+placebo.+OBJECTIVE:+Recently+a+randomized+placebo-controlled+phase+III+trial+of+biodegradable+polymers+containing+carmustine+has+demonstrated+a+significant+survival+benefit+for+patients+treated+with+local+chemotherapy.++CONCLUSION:+In+this+subgroup+analysis+of+a+phase+III+trial+population+both+the+clinical+progression+and+radiological+progression+were+significantly+delayed+in+patients+treated+with+local+chemotherapy,+resulting+in+an+increased+survival+time.+A+previous+placebo-controlled+trial+has+shown+that+biodegradable+1,3-bis+(2-chloroethyl)-1-nitrosourea+(BCNU)+wafers+(Gliadel+wafers)+prolong+survival+in+patients+with+recurrent+glioblastoma+multiforme.+A+previously+completed+phase+3+trial,+also+placebo+controlled,+in+32+patients+with+newly+diagnosed+malignant+glioma+also+demonstrated+a+survival+benefit+in+those+patients+treated+with+BCNU+wafers.+Median+survival+in+the+intent-to-treat+group+was+13.9+months+for+the+BCNU+wafer-treated+group+and+11.6+months+for+the+placebo-treated+group+(log-rank+P+-value+stratified+by+country+%3D+0.03),+with+a+29%25+reduction+in+the+risk+of+death+in+the+treatment+group.+When+adjusted+for+factors+affecting+survival,+the+treatment+effect+remained+positive+with+a+risk+reduction+of+28%25+(+P+%3D+0.03).++Controlled+release+delivery+of+carmustine+from+biodegradable+polymer+wafers+was+approved+as+an+adjunct+to+surgical+resection+in+the+treatment+of+recurrent+glioblastoma+multiforme+after+it+was+shown+in+clinical+trials+to+be+well+tolerated+and+effective.++Clinical+trials+have+demonstrated+significant+improvements+in+survival+and+quality+of+life+for+patients+after+complete+tumour+resection+and+BCNU+wafer+implantation.+BCNU+wafers+are+an+effective+means+of+increasing+survival+and+quality+of+life+in+patients+diagnosed+with+malignant+glioma,+and+are+a+valuable+addition+to+the+overall+multimodal+treatment+strategy+for+these+tumours.+CONCLUSIONS:+Carmustine+wafer+with+concurrent+TMZ+and+radiation+followed+by+rotational+chemotherapy+is+a+well+tolerated,+effective+therapy,+and+has+a+survival+benefit+compared+with+radiation+alone.+Median+overall+survival+in+14+studies+of+newly-diagnosed+patients+suggested+a+modest+improvement+versus+resection+followed+by+Stupp+protocol+or+resection+with+BCNU+wafers,+with+an+acceptable+and+manageable+safety+profile.+The+efficacy+of+carmustine+wafers+for+older+patients+with+glioblastoma+multiforme:+prolonging+survival.+DISCUSSION:+Older+patients+with+GBM+may+benefit+from+carmustine+wafers.+The+survival+for+older+patients+who+received+carmustine+wafers+is+significantly+longer+than+matched+patients+who+did+not+receive+carmustine+wafers.+For+glioblastoma+patients+who+received+%E2%89%A590%25+resection+in+the+BCNU+wafer+study,+median+survival+increased+for+BCNU+wafer+versus+placebo+(14.5+versus+12.4%C2%A0months,+respectively;+P%E2%80%89%3D%E2%80%890.02),+but+no+survival+increase+was+found+for+%3C90%25+resection+(11.7+versus+10.6%C2%A0months,+respectively;+P%E2%80%89%3D%E2%80%890.98).+A+wafer+impregnated+with+carmustine,+for+use+as+an+implant+after+surgical+removal+of+recurrent+GBM+showed+a+prolongation+in+the+median+survival+time+of+only+2+mo,+from+20+to+28+wk+in+a+study+with+a+total+of+222+patients.++No+clear+survival+benefit+associated+with+wafer+implantation+was+identified.+In+three+of+the+trials,+patients+with+GBM+who+received+carmustine+wafers+had+significantly+longer+median+survival+than+patients+who+did+not+receive+wafers.++TMZ+and+carmustine+(BCNU)+biodegradable+wafer+(Gliadel)+are+the+only+adjuvant+chemotherapies+that+have+improved+survival+in+randomised+GB+clinical+trials+.++The+carmustine+implant+wafer+was+demonstrated+to+improve+survival+in+blinded+placebo-controlled+trials+in+selected+patients+with+newly+diagnosed+or+recurrent+malignant+glioma,+with+little+increased+risk+of+adverse+events.++For+patients+undergoing+repeat+resection+for+malignant+glioma,+a+randomized,+blinded,+placebo-controlled+trial+demonstrated+a+median+survival+for+110+patients+who+received+carmustine+polymers+of+31+weeks+compared+with+23+weeks+for+122+patients+who+only+received+placebo+polymers.+Median+survival+was+improved+from+11.6+to+13.9+months+(P+%3D+0.03),+with+a+29%25+reduction+in+the+risk+of+death.+When+patients+with+glioblastoma+multiforme+alone+were+analyzed,+the+median+survival+improved+from+11.4+to+13.5+months,+but+this+improvement+was+not+statistically+significant.++OBJECT:+Locoregional+chemotherapy+with+carmustine+wafers,+positioned+at+surgery+and+followed+by+radiation+therapy,+has+been+shown+to+prolong+survival+in+patients+with+newly+diagnosed+glioblastoma,+as+has+concomitant+radiochemotherapy+with+temozolomide.+Following+the+resection+of+newly+diagnosed+or+recurrent+glioblastomas,+local+implantation+of+carmustine-impregnated+biodegradable+wafers+(Gliadel)+in+the+resection+cavity+constitutes+an+adjuvant+therapy+that+can+improve+the+possibilities+of+survival.+The+carmustine+implant+wafer+was+demonstrated+to+improve+survival+in+blinded+placebo-controlled+trials+in+selected+patients+with+newly+diagnosed+or+recurrent+malignant+glioma,+with+little+increased+risk+of+adverse+events.+However,+patients+with+carmustine+wafers+demonstrated+prolonged+survival+as+compared+to+patients+without+wafers.+The+median+survival+for+patients+with+carmustine+wafers+was+8.7+months,+while+median+survival+for+patients+without+wafers+was+5.5+months+(P%3D0.007).+Likewise,+in+subgroup+analysis,+patients+older+than+70+years+(P%3D0.0003)+and+75+years+(P%3D0.04)+who+had+carmustine+wafers+had+significantly+longer+survival+than+matched+patients+without+wafers.+Implantation+of+carmustine+wafers+did+not+significantly+improve+progression-free+survival+In+three+of+the+trials,+patients+with+GBM+who+received+carmustine+wafers+had+significantly+longer+median+survival+than+patients+who+did+not+receive+wafers+A+previous+placebo-controlled+trial+has+shown+that+biodegradable+1,3-bis+(2-chloroethyl)-1-nitrosourea+(BCNU)+wafers+(Gliadel+wafers)+prolong+survival+in+patients+with+recurrent+glioblastoma+multiforme+A+previously+completed+phase+3+trial,+also+placebo+controlled,+in+32+patients+with+newly+diagnosed+malignant+glioma+also+demonstrated+a+survival+benefit+in+those+patients+treated+with+BCNU+wafers+Following+the+resection+of+newly+diagnosed+or+recurrent+glioblastomas,+local+implantation+of+carmustine-impregnated+biodegradable+wafers+(Gliadel)+in+the+resection+cavity+constitutes+an+adjuvant+therapy+that+can+improve+the+possibilities+of+survival+Multimodal+treatment+with+carmustine+wafers,+radical+radiotherapy+and+concomitant+temozolomide+was+associated+with+improved+survival+The+carmustine+implant+wafer+was+demonstrated+to+improve+survival+in+blinded+placebo-controlled+trials+in+selected+patients+with+newly+diagnosed+or+recurrent+malignant+glioma,+with+little+increased+risk+of+adverse+events+TMZ+and+carmustine+(BCNU)+biodegradable+wafer+(Gliadel)+are+the+only+adjuvant+chemotherapies+that+have+improved+survival+in+randomised+GB+clinical+trials&tl=zh-CN&sl=en (Caused by SSLError(SSLEOFError(8, 'EOF occurred in violation of protocol (_ssl.c:1131)'))) At recurrence, treatment options include repeat surgery (with or without Gliadel wafer placement), reirradiation or systemic therapy.  DISCUSSION: Carmustine wafers for primary HGG surgery in accordance with the NICE TA121 were associated with a median survival of 15.3 months; this is improved compared with previously reported randomised trials. Multimodal treatment with carmustine wafers, radical radiotherapy and concomitant temozolomide was associated with improved survival. Gliadel wafer is a new approach to the treatment of glioblastoma, which involves controlled release delivery of carmustine from biodegradable polymer wafers. It has shown promising results and provides a silver lining for glioblastoma patients. For patient with and without Gliadel, median and 1-year RFS were 12.9 months and 52% vs. 14 months and 42%, respectively (p = 0.89). According to pathology, Gliadel did not influence OS of patients with Grade III or glioblastoma CONCLUSION: In patients with high-grade gliomas, adding Gliadel before performing a Stupp protocol did not improve survival. Randomized phase III trials have shown significant improvement of survival 1, 2, and 3 years after implantation of 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) wafers for patients with newly diagnosed malignant glioma.  CONCLUSIONS: The combination of aggressive resection, Gliadel wafer implantation, and GKS in addition to standard fractionated RT in selected patients resulted in increased local control and increased survival compared with a historical control group treated with surgery and involved-field RT alone. OBJECT: Gliadel (BCNU) wafer and concomitant temozolomide (TMZ) therapy, when used individually as adjuvant therapies, extend survival from that achieved by resection and radiation therapy (XRT) for glioblastoma multiforme (GBM).  BACKGROUND: Gliadel (polifeprosan 20 with carmustine [BCNU] implant) is commonly used for local delivery of BCNU to high-grade gliomas after resection and is associated with increased survival. Temozolomide administered according to this protocol produced a median survival benefit of 2 months in glioblastomas, and carmustine a similar benefit in high-grade gliomas. Analysis of a large trial by Westphal and colleagues (n = 240) showed a 29% risk reduction (P = 0.03) in the BCNU wafer-treated group over the course of the 30-month trial. Median survival of patients treated with BCNU wafers was 13.8 months vs 11.6 months in placebo-treated patients (P = 0.017) with a hazard ratio of 0.73 (P = 0.018), representing a 27% significant risk reduction. This survival advantage was maintained at 1, 2, and 3 years and was statistically significant (P = 0.01) at 3 years. CONCLUSION: Malignant glioma patients treated with BCNU wafers at the time of initial surgery in combination with radiation therapy demonstrated a survival advantage at 2 and 3 years follow-up compared with placebo. OBJECTIVE: Recently a randomized placebo-controlled phase III trial of biodegradable polymers containing carmustine has demonstrated a significant survival benefit for patients treated with local chemotherapy.  CONCLUSION: In this subgroup analysis of a phase III trial population both the clinical progression and radiological progression were significantly delayed in patients treated with local chemotherapy, resulting in an increased survival time. A previous placebo-controlled trial has shown that biodegradable 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) wafers (Gliadel wafers) prolong survival in patients with recurrent glioblastoma multiforme. A previously completed phase 3 trial, also placebo controlled, in 32 patients with newly diagnosed malignant glioma also demonstrated a survival benefit in those patients treated with BCNU wafers. Median survival in the intent-to-treat group was 13.9 months for the BCNU wafer-treated group and 11.6 months for the placebo-treated group (log-rank P -value stratified by country = 0.03), with a 29% reduction in the risk of death in the treatment group. When adjusted for factors affecting survival, the treatment effect remained positive with a risk reduction of 28% ( P = 0.03).  Controlled release delivery of carmustine from biodegradable polymer wafers was approved as an adjunct to surgical resection in the treatment of recurrent glioblastoma multiforme after it was shown in clinical trials to be well tolerated and effective.  Clinical trials have demonstrated significant improvements in survival and quality of life for patients after complete tumour resection and BCNU wafer implantation. BCNU wafers are an effective means of increasing survival and quality of life in patients diagnosed with malignant glioma, and are a valuable addition to the overall multimodal treatment strategy for these tumours. CONCLUSIONS: Carmustine wafer with concurrent TMZ and radiation followed by rotational chemotherapy is a well tolerated, effective therapy, and has a survival benefit compared with radiation alone. Median overall survival in 14 studies of newly-diagnosed patients suggested a modest improvement versus resection followed by Stupp protocol or resection with BCNU wafers, with an acceptable and manageable safety profile. The efficacy of carmustine wafers for older patients with glioblastoma multiforme: prolonging survival. DISCUSSION: Older patients with GBM may benefit from carmustine wafers. The survival for older patients who received carmustine wafers is significantly longer than matched patients who did not receive carmustine wafers. For glioblastoma patients who received 90% resection in the BCNU wafer study, median survival increased for BCNU wafer versus placebo (14.5 versus 12.4months, respectively; P=0.02), but no survival increase was found for <90% resection (11.7 versus 10.6months, respectively; P=0.98). A wafer impregnated with carmustine, for use as an implant after surgical removal of recurrent GBM showed a prolongation in the median survival time of only 2 mo, from 20 to 28 wk in a study with a total of 222 patients.  No clear survival benefit associated with wafer implantation was identified. In three of the trials, patients with GBM who received carmustine wafers had significantly longer median survival than patients who did not receive wafers.  TMZ and carmustine (BCNU) biodegradable wafer (Gliadel) are the only adjuvant chemotherapies that have improved survival in randomised GB clinical trials .  The carmustine implant wafer was demonstrated to improve survival in blinded placebo-controlled trials in selected patients with newly diagnosed or recurrent malignant glioma, with little increased risk of adverse events.  For patients undergoing repeat resection for malignant glioma, a randomized, blinded, placebo-controlled trial demonstrated a median survival for 110 patients who received carmustine polymers of 31 weeks compared with 23 weeks for 122 patients who only received placebo polymers. Median survival was improved from 11.6 to 13.9 months (P = 0.03), with a 29% reduction in the risk of death. When patients with glioblastoma multiforme alone were analyzed, the median survival improved from 11.4 to 13.5 months, but this improvement was not statistically significant.  OBJECT: Locoregional chemotherapy with carmustine wafers, positioned at surgery and followed by radiation therapy, has been shown to prolong survival in patients with newly diagnosed glioblastoma, as has concomitant radiochemotherapy with temozolomide. Following the resection of newly diagnosed or recurrent glioblastomas, local implantation of carmustine-impregnated biodegradable wafers (Gliadel) in the resection cavity constitutes an adjuvant therapy that can improve the possibilities of survival. The carmustine implant wafer was demonstrated to improve survival in blinded placebo-controlled trials in selected patients with newly diagnosed or recurrent malignant glioma, with little increased risk of adverse events. However, patients with carmustine wafers demonstrated prolonged survival as compared to patients without wafers. The median survival for patients with carmustine wafers was 8.7 months, while median survival for patients without wafers was 5.5 months (P=0.007). Likewise, in subgroup analysis, patients older than 70 years (P=0.0003) and 75 years (P=0.04) who had carmustine wafers had significantly longer survival than matched patients without wafers. Implantation of carmustine wafers did not significantly improve progression-free survival In three of the trials, patients with GBM who received carmustine wafers had significantly longer median survival than patients who did not receive wafers A previous placebo-controlled trial has shown that biodegradable 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) wafers (Gliadel wafers) prolong survival in patients with recurrent glioblastoma multiforme A previously completed phase 3 trial, also placebo controlled, in 32 patients with newly diagnosed malignant glioma also demonstrated a survival benefit in those patients treated with BCNU wafers Following the resection of newly diagnosed or recurrent glioblastomas, local implantation of carmustine-impregnated biodegradable wafers (Gliadel) in the resection cavity constitutes an adjuvant therapy that can improve the possibilities of survival Multimodal treatment with carmustine wafers, radical radiotherapy and concomitant temozolomide was associated with improved survival The carmustine implant wafer was demonstrated to improve survival in blinded placebo-controlled trials in selected patients with newly diagnosed or recurrent malignant glioma, with little increased risk of adverse events TMZ and carmustine (BCNU) biodegradable wafer (Gliadel) are the only adjuvant chemotherapies that have improved survival in randomised GB clinical trials./train.json: 227it [17:31,  2.90s/it]./train.json: 228it [17:34,  2.81s/it]./train.json: 229it [17:36,  2.71s/it]./train.json: 230it [17:39,  2.70s/it]./train.json: 231it [17:42,  2.70s/it]./train.json: 232it [17:45,  2.78s/it]./train.json: 233it [17:47,  2.65s/it]./train.json: 234it [17:50,  2.84s/it]./train.json: 235it [17:53,  2.70s/it]
HTTPSConnectionPool(host='translate.google.com', port=443): Max retries exceeded with url: /m?q=Is+Dicer+part+of+the+RISC+loading+complex?&tl=zh-CN&sl=en (Caused by SSLError(SSLEOFError(8, 'EOF occurred in violation of protocol (_ssl.c:1131)'))) Is Dicer part of the RISC loading complex?
HTTPSConnectionPool(host='translate.google.com', port=443): Max retries exceeded with url: /m?q=to+explore+the+effect+of+ageing+on+renal+function+with+cystatin+C+as+the+marker+of+glomerular+filtration+rate+(GFR)+in+the+general+population+without+vascular+disease+or+diabetes.+Cystatin+C,+a+more+specific+kidney+function+biomarker,+was+also+elevated+at+24+h+after+CLP.+This+study+evaluated+FGF-23+as+well+as+traditional+markers+of+kidney+disease,+namely+urine+albumin-to-creatinine+ratio+(UACR)+and+creatinine-cystatin+C+estimated+GFR+(eGFRCrCyC),+as+risk+factors+for+AKI+in+elderly+individuals.++he+primary+predictor+was+estimated+GFR+(eGFR)+calculated+using+serum+cystatin+C+(eGFR(cys)).+A+number+of+recent+reports+have+suggested+that+the+cystatin+C/creatinine+(CysC/Cr)+ratio+might+be+a+useful+biomarker+of+renal+function+in+pediatric+patients.+The+CKD-EPI+equation+using+cystatin+C+was+the+most+precise+method+of+renal+function+evaluation+in+patients+with+neurogenic+bladder.+Serum+cystatin+C+(CysC)+is+an+endogenous+marker+of+kidney+function.+The+urinary+content+of+CysC+reflects+tubular+epithelial+dysfunction+whereas+that+of+NGAL+also+characterizes+tubular+atrophy.+Estimated+kidney+function+based+on+serum+cystatin+C++:+Several+formulas+for+glomerular+filtration+rate+(GFR)+estimation,+based+on+serum+creatinine+or+cystatin+C,+have+been+proposed.++he+highest+and+lowest+eGFR+levels+corresponded+to+the+cystatin+C-based+and+MDRD-4+equations,+respectively.++The+Chronic+Kidney+Disease+Epidemiology+Collaboration+(CKD-EPI)+recently+proposed+an+equation+to+estimate+GFR+in+subjects+without+cirrhosis+using+both+serum+creatinine+and+cystatin+C+levels.+Emerging+evidence+has+shown+that+cystatin+C+may+improve+classification+of+glomerular+filtration+rate+for+defining+chronic+kidney+disease+in+certain+clinical+populations+and+assist+in+understanding+the+complications+of+chronic+kidney+disease+Beta-trace+protein+(BTP)+and+cystatin+C+(CysC)+are+novel+biomarkers+of+renal+function.++Cystatin+C+could+improve+chronic+kidney+disease+(CKD)+classification+in+HIV-infected+women+relative+to+serum+creatinine.++Iohexol+clearance+and+cystatin+C+formulae+identify+a+greater+proportion+of+patients+with+a+GFR+%3C60+mL/min/1.73+m(2),+which+also+predicts+the+development+of+AKI.++Cystatin+C+was+recently+reported+to+be+an+endogenous+surrogate+of+kidney+function,+and+a+high+level+of+cystatin+C+is+reported+to+be+a+strong+predictor+of+CVD;+Studies+that+have+simultaneously+compared+measured+GFR+and+estimated+GFR+(using+endogenous+filtration+markers+such+as+creatinine,+or+newer+ones+such+as+cystatin+C+or+%CE%B2-trace+protein)&tl=zh-CN&sl=en (Caused by SSLError(SSLEOFError(8, 'EOF occurred in violation of protocol (_ssl.c:1131)'))) to explore the effect of ageing on renal function with cystatin C as the marker of glomerular filtration rate (GFR) in the general population without vascular disease or diabetes. Cystatin C, a more specific kidney function biomarker, was also elevated at 24 h after CLP. This study evaluated FGF-23 as well as traditional markers of kidney disease, namely urine albumin-to-creatinine ratio (UACR) and creatinine-cystatin C estimated GFR (eGFRCrCyC), as risk factors for AKI in elderly individuals.  he primary predictor was estimated GFR (eGFR) calculated using serum cystatin C (eGFR(cys)). A number of recent reports have suggested that the cystatin C/creatinine (CysC/Cr) ratio might be a useful biomarker of renal function in pediatric patients. The CKD-EPI equation using cystatin C was the most precise method of renal function evaluation in patients with neurogenic bladder. Serum cystatin C (CysC) is an endogenous marker of kidney function. The urinary content of CysC reflects tubular epithelial dysfunction whereas that of NGAL also characterizes tubular atrophy. Estimated kidney function based on serum cystatin C  : Several formulas for glomerular filtration rate (GFR) estimation, based on serum creatinine or cystatin C, have been proposed.  he highest and lowest eGFR levels corresponded to the cystatin C-based and MDRD-4 equations, respectively.  The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) recently proposed an equation to estimate GFR in subjects without cirrhosis using both serum creatinine and cystatin C levels. Emerging evidence has shown that cystatin C may improve classification of glomerular filtration rate for defining chronic kidney disease in certain clinical populations and assist in understanding the complications of chronic kidney disease Beta-trace protein (BTP) and cystatin C (CysC) are novel biomarkers of renal function.  Cystatin C could improve chronic kidney disease (CKD) classification in HIV-infected women relative to serum creatinine.  Iohexol clearance and cystatin C formulae identify a greater proportion of patients with a GFR <60 mL/min/1.73 m(2), which also predicts the development of AKI.  Cystatin C was recently reported to be an endogenous surrogate of kidney function, and a high level of cystatin C is reported to be a strong predictor of CVD; Studies that have simultaneously compared measured GFR and estimated GFR (using endogenous filtration markers such as creatinine, or newer ones such as cystatin C or -trace protein)
HTTPSConnectionPool(host='translate.google.com', port=443): Max retries exceeded with url: /m?q=Here+we+observe+that+mutation+rate,+as+reflected+in+recent+evolutionary+divergence+and+human+nucleotide+diversity,+is+markedly+increased+in+later-replicating+regions+of+the+human+genome+ll+classes+of+substitutions+are+affected,+suggesting+a+generalized+mechanism+involving+replication+time-dependent+DNA+damage+We+show+that+mutation+rate+varies+6-fold+across+a+single+chromosome,+that+this+variation+is+correlated+with+replication+timing,+and+we+propose+a+model+to+explain+this+variation+that+relies+on+the+temporal+separation+of+two+processes+for+replicating+past+damaged+DNA:+error-free+DNA+damage+tolerance+and+translesion+synthesis.+Recent+studies+revealed+a+long+suspected+replication-timing+effect+on+mutation+rate,+but+the+mechanisms+that+regulate+the+increase+in+mutation+rate+as+the+genome+is+replicated+remain+unclear.++DNA+repair+systems,+in+general,+are+less+efficient+in+late+replicating+heterochromatic+regions+compared+to+early+replicating+euchromatic+regions+of+the+genome.+The+mutational+profile+of+the+yeast+genome+is+shaped+by+replication+the+mutation+rate+increases+with+the+replication+timing+by+more+than+30%25+between+the+earliest+and+the+latest+replicating+regions.+Thus,+we+show+that+the+leading+replicating+strands+present+an+excess+of+C+over+G+and+of+A+over+T+in+the+genome+of+S.+cerevisiae+(reciprocally+an+excess+of+G+%2B+T+over+C+%2B+A+in+lagging+strands)+Late-replicating+domains+have+higher+divergence+and+diversity+in+Drosophila+melanogaster+Recent+evidence+also+suggests+that+late+replication+is+associated+with+high+mutability+in+yeast.+Limited+evidence+from+one+chromosome+arm+in+Drosophila+melanogaster+suggests+the+opposite+pattern,+with+regions+overlapping+early-firing+origins+showing+increased+levels+of+diversity+and+divergence+The+mutation+rate+for+DNA+mismatch+repair+null+strains+was+approximately+1+mutation+per+genome+per+generation,+225-fold+greater+than+the+wild-type+rate.+The+mutations+were+distributed+randomly+throughout+the+genome,+independent+of+replication+timing.+Many+single-nucleotide+substitutions+in+cancer+genomes+arise+because+of+errors+in+DNA+replication,+which+is+spatio-temporally+stratified.+Here+we+propose+that+DNA+replication+patterns+help+shape+the+mutational+landscapes+of+normal+and+cancer+genomes+Using+data+on+five+fully+sequenced+cancer+types+and+two+personal+genomes,+we+determined+that+the+frequency+of+intergenic+single-nucleotide+substitution+is+significantly+higher+in+late+DNA+replication+timing+regions,+even+after+controlling+for+a+number+of+genomic+features+we+found+that+genomic+regions+in+close+spatial+proximity+to+late-replicating+domains+display+similar+mutation+spectra+as+the+late-replicating+regions+themselves+In+addition,+certain+chromosome+rearrangements+found+in+cancer+cells+and+in+cells+exposed+to+ionizing+radiation+display+a+significant+delay+in+replication+timing+of+%3E3+hours+that+affects+the+entire+chromosome(2,3).+Recent+work+from+our+lab+indicates+that+disruption+of+discrete+cis-acting+autosomal+loci+result+in+an+extremely+late+replicating+phenotype+that+affects+the+entire+chromosome(4).+A+conservative+estimate+is+that+at+least+1-2%25+of+new+deleterious+mutations+affect+some+aspect+of+DNA+replication,+repair,+or+chromosome+segregation.+Since+deleterious+mutations+can+have+an+effect+even+as+heterozygotes,+this+mutation+accumulation+can+create+an+inherited+background+of+late-acting+mutations+that+themselves+enhance+mutation+rate.+Drake+calculates+that+lytic+RNA+viruses+display+spontaneous+mutation+rates+of+approximately+one+per+genome+while+most+have+mutation+rates+that+are+approximately+0.1+per+genome+(Drake+1993).+This+constancy+of+germline+mutation+rates+among+microbial+species+need+not+necessarily+mean+constancy+of+the+somatic+mutation+rates.+A+recent+flurry+of+reports+correlates+replication+timing+(RT)+with+mutation+rates+during+both+evolution+and+cancer.+DNA+replication+timing,+genome+stability+and+cancer:+late+and/or+delayed+DNA+replication+timing+is+associated+with+increased+genomic+instability.+Since+deleterious+mutations+can+have+an+effect+even+as+heterozygotes,+this+mutation+accumulation+can+create+an+inherited+background+of+late-acting+mutations+that+themselves+enhance+mutation+rate.+In+addition,+this+method+allows+for+the+unambiguous+identification+of+chromosomal+rearrangements+that+correlate+with+changes+in+replication+timing+that+affect+the+entire+chromosome.&tl=zh-CN&sl=en (Caused by SSLError(SSLEOFError(8, 'EOF occurred in violation of protocol (_ssl.c:1131)'))) ./train.json: 236it [17:55,  2.67s/it]./train.json: 237it [17:58,  2.61s/it]Here we observe that mutation rate, as reflected in recent evolutionary divergence and human nucleotide diversity, is markedly increased in later-replicating regions of the human genome ll classes of substitutions are affected, suggesting a generalized mechanism involving replication time-dependent DNA damage We show that mutation rate varies 6-fold across a single chromosome, that this variation is correlated with replication timing, and we propose a model to explain this variation that relies on the temporal separation of two processes for replicating past damaged DNA: error-free DNA damage tolerance and translesion synthesis. Recent studies revealed a long suspected replication-timing effect on mutation rate, but the mechanisms that regulate the increase in mutation rate as the genome is replicated remain unclear.  DNA repair systems, in general, are less efficient in late replicating heterochromatic regions compared to early replicating euchromatic regions of the genome. The mutational profile of the yeast genome is shaped by replication the mutation rate increases with the replication timing by more than 30% between the earliest and the latest replicating regions. Thus, we show that the leading replicating strands present an excess of C over G and of A over T in the genome of S. cerevisiae (reciprocally an excess of G + T over C + A in lagging strands) Late-replicating domains have higher divergence and diversity in Drosophila melanogaster Recent evidence also suggests that late replication is associated with high mutability in yeast. Limited evidence from one chromosome arm in Drosophila melanogaster suggests the opposite pattern, with regions overlapping early-firing origins showing increased levels of diversity and divergence The mutation rate for DNA mismatch repair null strains was approximately 1 mutation per genome per generation, 225-fold greater than the wild-type rate. The mutations were distributed randomly throughout the genome, independent of replication timing. Many single-nucleotide substitutions in cancer genomes arise because of errors in DNA replication, which is spatio-temporally stratified. Here we propose that DNA replication patterns help shape the mutational landscapes of normal and cancer genomes Using data on five fully sequenced cancer types and two personal genomes, we determined that the frequency of intergenic single-nucleotide substitution is significantly higher in late DNA replication timing regions, even after controlling for a number of genomic features we found that genomic regions in close spatial proximity to late-replicating domains display similar mutation spectra as the late-replicating regions themselves In addition, certain chromosome rearrangements found in cancer cells and in cells exposed to ionizing radiation display a significant delay in replication timing of >3 hours that affects the entire chromosome(2,3). Recent work from our lab indicates that disruption of discrete cis-acting autosomal loci result in an extremely late replicating phenotype that affects the entire chromosome(4). A conservative estimate is that at least 1-2% of new deleterious mutations affect some aspect of DNA replication, repair, or chromosome segregation. Since deleterious mutations can have an effect even as heterozygotes, this mutation accumulation can create an inherited background of late-acting mutations that themselves enhance mutation rate. Drake calculates that lytic RNA viruses display spontaneous mutation rates of approximately one per genome while most have mutation rates that are approximately 0.1 per genome (Drake 1993). This constancy of germline mutation rates among microbial species need not necessarily mean constancy of the somatic mutation rates. A recent flurry of reports correlates replication timing (RT) with mutation rates during both evolution and cancer. DNA replication timing, genome stability and cancer: late and/or delayed DNA replication timing is associated with increased genomic instability. Since deleterious mutations can have an effect even as heterozygotes, this mutation accumulation can create an inherited background of late-acting mutations that themselves enhance mutation rate. In addition, this method allows for the unambiguous identification of chromosomal rearrangements that correlate with changes in replication timing that affect the entire chromosome.
HTTPSConnectionPool(host='translate.google.com', port=443): Max retries exceeded with url: /m?q=CONCLUSION:+Patients+assigned+a+higher+serum+magnesium+concentration+had+a+reduced+incidence+of+vasospasm+as+seen+by+angiography,+but+the+difference+was+not+statistically+significant.+Clinically+significant+outcomes+were+not+different+between+groups.+158+patients+(26%C2%B72%25)+had+poor+outcome+in+the+magnesium+group+compared+with+151+(25%C2%B73%25)+in+the+placebo+group+(risk+ratio+%5BRR%5D+1%C2%B703,+95%25+CI+0%C2%B785-1%C2%B725).+Our+updated+meta-analysis+of+seven+randomised+trials+involving+2047+patients+shows+that+magnesium+is+not+superior+to+placebo+for+reduction+of+poor+outcome+after+aneurysmal+subarachnoid+haemorrhage+(RR+0%C2%B796,+95%25+CI+0%C2%B786-1%C2%B708).+INTERPRETATION:+Intravenous+magnesium+sulphate+does+not+improve+clinical+outcome+after+aneurysmal+subarachnoid+haemorrhage,+therefore+routine+administration+of+magnesium+cannot+be+recommended.++There+is+a+tendency+in+the+magnesium+group+to+have+better+outcomes.++Due+to+inconsistently+reported+benefits+and+the+occurrence+of+side+effects,+phase+II+data+suggested+that+intravenous+magnesium+for+SAH+provided+either+no+overall+net+benefit+or+uncertain+trade-offs.+Benefit+was+likewise+not+supported+in+the+single+phase+III+clinical+trial.+tatistically+significant+clinical+benefits+could+not+be+demonstrated+for+the+other+drugs+(clazosentan,+statins,+and+magnesium).+CONCLUSIONS:+Insufficient+evidence+is+available+to+support+the+use+of+the+triple-H+therapy,+clazosentan,+statins,+or+magnesium+sulfate+for+the+prevention+of+cerebral+vasospasm+following+subarachnoid+hemorrhage.++Magnesium+sulfate+decreased+the+rate+of+cerebral+infarction,+but+not+of+DCI+or+poor+functional+outcome.+Regarding+outcome,+a+beneficial+effect+of+magnesium+sulfate+on+outcome+can+not+be+ruled+out+because+of+sample+size+limitations.+CONCLUSIONS:+The+present+findings+do+not+lend+support+to+a+beneficial+effect+of+magnesium+sulphate+infusion+on+delayed+cerebral+infarction.+The+reduction+in+DCI+and+improvement+in+the+clinical+outcomes+of+aneurysmal+SAH+patients+following+magnesium+sulphate+infusion+observed+in+previous+pilot+studies+are+not+confirmed,+although+a+beneficial+effect+cannot+be+ruled+out+because+of+sample+size+limitation.+Favorable+outcome+(Good+recovery+and+moderate+disability,+as+defined+by+Glasgow+Outcome+Scale)+was+achieved+in+20+of+30+(67%25)+patients+receiving+magnesium+sulfate+infusion+and+16+of+30+(53%25)+patients+receiving+placebo+treatment,+p+%3D+0.292,+odds+ratio+1.750,+95%25+CI+0.616-4.974.+Similarly,+the+pooled+odds+ratio+for+favorable+outcome+is+1.598,+95%25+CI+1.074-2.377,+statistically+significant.++RESULTS:+The+worst+clinical+outcomes+at+6+months+were+seen+in+MgSO(4)+group+patients,+with+mean+plasma+magnesium+concentrations+in+the+fourth+quartile,+and+in+placebo+group+patients,+with+mean+such+concentrations+in+the+third+and+fourth+quartiles.+CONCLUSIONS:+No+evidence+was+found+to+suggest+that+a+higher+mean+plasma+magnesium+concentration+improves+clinical+outcomes.+On+the+contrary,+we+found+an+association+between+high+plasma+magnesium+concentration+and+worse+clinical+outcomes.+The+proportions+of+patients+with+a+favorable+outcome+at+6+months+(Extended+Glasgow+Outcome+Scale+5+to+8)+were+similar,+64%25+in+the+magnesium+sulfate+group+and+63%25+in+the+saline+group+(OR,+1.0;+95%25+CI,+0.7+to+1.6).+Secondary+outcome+analyses+(modified+Rankin+Scale,+Barthel+Index,+Short+Form+36,+and+clinical+vasospasm)+also+showed+no+significant+differences+between+the+2+groups.++CONCLUSIONS:+The+results+do+not+support+a+clinical+benefit+of+intravenous+magnesium+sulfate+infusion+over+placebo+infusion+in+patients+with+acute+aneurysmal+subarachnoid+hemorrhage.+Magnesium+infusion+reduced+the+risk+of+poor+outcome+and+delayed+cerebral+ischemia+(DCI):+the+relative+risk+was+0.62+(95%25+confidence+interval+(CI)+0.46-0.83)+and+0.73+(95%25+CI+0.53-1.00),+respectively.++CONCLUSION:+The+meta-analysis+suggests+that+intravenous+magnesium+therapy+reduces+the+risk+of+DCI+and+poor+outcome+after+aneurysmal+SAH.++The+incidence+of+delayed+ischemic+infarction+was+significantly+lower+in+magnesium-treated+patients+(22%25+vs.+51%25;+p+%3D+.002);+34+of+54+magnesium+patients+and+27+of+53+control+patients+reached+good+outcome+(p+%3D+.209).+BACKGROUND:+A+meta-analysis+of+current+data+suggests+that+magnesium+sulfate+infusion+improves+the+outcome+after+aneurysmal+subarachnoid+hemorrhage+through+a+reduction+in+delayed+ischemic+neurological+deficit.++These+data+imply+that+intravenous+magnesium+therapy,+besides+a+supposed+beneficial+effect+on+outcome,+also+provides+pain+relief+for+SAH+patients,+for+whom+it+might+also+improve+functional+outcome.+Preliminary+evidence+has+suggested+that+magnesium+sulfate+infusion+reduces+delayed+ischemic+neurological+deficit+and+improves+clinical+outcome+after+aneurysmal+subarachnoid+hemorrhage.++In+a+phase+II+randomized+clinical+trial+of+283+patients,+magnesium+treatment+reduced+the+risk+of+DCI+by+34%25+and+of+poor+outcome+by+23%25.+BACKGROUND:+Recent+studies+suggest+that+high-dose+MgSO4+therapy+is+safe+and+reduces+the+incidence+of+DIND+and+subsequent+poor+outcome+after+SAH.++On-treatment+analysis+showed+a+significantly+better+outcome+after+3+months+(P+%3D+.017)+and+a+trend+toward+better+outcome+after+1+year+(P+%3D+.083).+++CONCLUSIONS:+High-dose+MgSO4+therapy+might+be+efficient+as+a+prophylactic+adjacent+therapy+after+SAH+to+reduce+the+risk+for+poor+outcome.++There+was+no+significant+difference+in+mortality+rate+at+discharge+(p+%3D+0.328).+A+trend+toward+improved+outcome+as+measured+by+the+modifed+Rankin+Scale+(p+%3D+0.084),+but+not+the+Glasgow+Outcome+Scale+(p+%3D+1.0),+was+seen+in+the+MgSO4+treated+group.+CONCLUSIONS:+Analysis+of+the+results+suggests+that+MgSO4+infusion+may+have+a+role+in+cerebral+vasospasm+prophylaxis+if+therapy+is+initiated+within+48+hours+of+aneurysm+rupture.+There+was,+however,+no+difference+between+groups+in+functional+recovery+or+Glasgow+Outcome+Scale+score.++Patients+receiving+MgSO4+tended+to+have+fewer+neurological+deficits,+better+functional+recovery+and+an+improved+score+in+GOS.++CONCLUSIONS:+MgSO4+infusion+after+aneurysmal+SAH+is+well+tolerated+and+may+be+useful+in+producing+better+outcome.+CONCLUSION:+Magnesium+did+not+seem+to+interfere+in+vasospasm+frequency+but+apparently+acted+favorably+in+decreasing+morbidity+and+length+of+hospital+stay.+None+of+the+patients+died;+no+CT+evidence+of+ischemic+infarction+was+present;+and+most+had+good+outcomes+(GOS+5+in+10+patients;+GOS+4+in+8+patients).+At+that+time,+18+patients+in+the+treatment+group+and+6+in+the+placebo+group+had+an+excellent+outcome+(risk+ratio,+3.4;+95%25+CI,+1.3+to+8.9).+CONCLUSIONS:+This+study+suggests+that+magnesium+reduces+DCI+and+subsequent+poor+outcome,+but+the+results+are+not+yet+definitive.++We+observed+a+trend+in+which+a+higher+percentage+of+patients+obtained+GOS+scores+of+4+or+5+in+the+group+treated+with+MgSO4,+but+the+trend+did+not+reach+a+statistically+significant+level.++Magnesium+sulfate+treatment+improves+outcome+in+patients+with+subarachnoid+hemorrhage:+a+meta-analysis+study.+BACKGROUND+AND+PURPOSE:+Pilot+clinical+trials+using+magnesium+sulfate+in+patients+with+acute+aneurysmal+subarachnoid+hemorrhage+have+reported+trends+toward+improvement+in+clinical+outcomes.+Preliminary+evidence+has+suggested+that+magnesium+sulfate+infusion+reduces+delayed+ischemic+neurological+deficit+and+improves+clinical+outcome+after+aneurysmal+subarachnoid+hemorrhage.+Our+results+indicate+that+although+there+was+reduced+likelihood+of+a+poor+outcome+for+patients+treated+with+magnesium+sulfate+after+SAH,+patient+mortality+was+not+improved.+CONCLUSION:+Administration+of+intra-arterial+magnesium+sulfate+in+combination+with+nicardipine+was+well+tolerated+in+patients+with+subarachnoid+hemorrhage+and+cerebral+vasospasm+without+a+significant+change+in+MAP+and+ICP.+Current+evidence+does+not+support+the+prophylactic+use+of+magnesium+sulfate+in+aneurysmal+subarachnoid+hemorrhage+Preliminary+evidence+has+suggested+that+magnesium+sulfate+infusion+reduces+delayed+ischemic+neurological+deficit+and+improves+clinical+outcome+after+aneurysmal+subarachnoid+hemorrhage+A+meta-analysis+of+current+data+suggests+that+magnesium+sulfate+infusion+improves+the+outcome+after+aneurysmal+subarachnoid+hemorrhage+through+a+reduction+in+delayed+ischemic+neurological+deficit+Despite+the+publication+of+several+randomized+controlled+studies,+there+is+still+much+debate+on+whether+magnesium+sulfate+improves+outcome+in+patients+with+aneurysmal+subarachnoid+hemorrhage+Magnesium+sulphate+is+a+neuroprotective+agent+that+might+improve+outcome+after+aneurysmal+subarachnoid+haemorrhage+by+reducing+the+occurrence+or+improving+the+outcome+of+delayed+cerebral+ischaemia&tl=zh-CN&sl=en (Caused by SSLError(SSLEOFError(8, 'EOF occurred in violation of protocol (_ssl.c:1131)'))) CONCLUSION: Patients assigned a higher serum magnesium concentration had a reduced incidence of vasospasm as seen by angiography, but the difference was not statistically significant. Clinically significant outcomes were not different between groups. 158 patients (262%) had poor outcome in the magnesium group compared with 151 (253%) in the placebo group (risk ratio [RR] 103, 95% CI 085-125). Our updated meta-analysis of seven randomised trials involving 2047 patients shows that magnesium is not superior to placebo for reduction of poor outcome after aneurysmal subarachnoid haemorrhage (RR 096, 95% CI 086-108). INTERPRETATION: Intravenous magnesium sulphate does not improve clinical outcome after aneurysmal subarachnoid haemorrhage, therefore routine administration of magnesium cannot be recommended.  There is a tendency in the magnesium group to have better outcomes.  Due to inconsistently reported benefits and the occurrence of side effects, phase II data suggested that intravenous magnesium for SAH provided either no overall net benefit or uncertain trade-offs. Benefit was likewise not supported in the single phase III clinical trial. tatistically significant clinical benefits could not be demonstrated for the other drugs (clazosentan, statins, and magnesium). CONCLUSIONS: Insufficient evidence is available to support the use of the triple-H therapy, clazosentan, statins, or magnesium sulfate for the prevention of cerebral vasospasm following subarachnoid hemorrhage.  Magnesium sulfate decreased the rate of cerebral infarction, but not of DCI or poor functional outcome. Regarding outcome, a beneficial effect of magnesium sulfate on outcome can not be ruled out because of sample size limitations. CONCLUSIONS: The present findings do not lend support to a beneficial effect of magnesium sulphate infusion on delayed cerebral infarction. The reduction in DCI and improvement in the clinical outcomes of aneurysmal SAH patients following magnesium sulphate infusion observed in previous pilot studies are not confirmed, although a beneficial effect cannot be ruled out because of sample size limitation. Favorable outcome (Good recovery and moderate disability, as defined by Glasgow Outcome Scale) was achieved in 20 of 30 (67%) patients receiving magnesium sulfate infusion and 16 of 30 (53%) patients receiving placebo treatment, p = 0.292, odds ratio 1.750, 95% CI 0.616-4.974. Similarly, the pooled odds ratio for favorable outcome is 1.598, 95% CI 1.074-2.377, statistically significant.  RESULTS: The worst clinical outcomes at 6 months were seen in MgSO(4) group patients, with mean plasma magnesium concentrations in the fourth quartile, and in placebo group patients, with mean such concentrations in the third and fourth quartiles. CONCLUSIONS: No evidence was found to suggest that a higher mean plasma magnesium concentration improves clinical outcomes. On the contrary, we found an association between high plasma magnesium concentration and worse clinical outcomes. The proportions of patients with a favorable outcome at 6 months (Extended Glasgow Outcome Scale 5 to 8) were similar, 64% in the magnesium sulfate group and 63% in the saline group (OR, 1.0; 95% CI, 0.7 to 1.6). Secondary outcome analyses (modified Rankin Scale, Barthel Index, Short Form 36, and clinical vasospasm) also showed no significant differences between the 2 groups.  CONCLUSIONS: The results do not support a clinical benefit of intravenous magnesium sulfate infusion over placebo infusion in patients with acute aneurysmal subarachnoid hemorrhage. Magnesium infusion reduced the risk of poor outcome and delayed cerebral ischemia (DCI): the relative risk was 0.62 (95% confidence interval (CI) 0.46-0.83) and 0.73 (95% CI 0.53-1.00), respectively.  CONCLUSION: The meta-analysis suggests that intravenous magnesium therapy reduces the risk of DCI and poor outcome after aneurysmal SAH.  The incidence of delayed ischemic infarction was significantly lower in magnesium-treated patients (22% vs. 51%; p = .002); 34 of 54 magnesium patients and 27 of 53 control patients reached good outcome (p = .209). BACKGROUND: A meta-analysis of current data suggests that magnesium sulfate infusion improves the outcome after aneurysmal subarachnoid hemorrhage through a reduction in delayed ischemic neurological deficit.  These data imply that intravenous magnesium therapy, besides a supposed beneficial effect on outcome, also provides pain relief for SAH patients, for whom it might also improve functional outcome. Preliminary evidence has suggested that magnesium sulfate infusion reduces delayed ischemic neurological deficit and improves clinical outcome after aneurysmal subarachnoid hemorrhage.  In a phase II randomized clinical trial of 283 patients, magnesium treatment reduced the risk of DCI by 34% and of poor outcome by 23%. BACKGROUND: Recent studies suggest that high-dose MgSO4 therapy is safe and reduces the incidence of DIND and subsequent poor outcome after SAH.  On-treatment analysis showed a significantly better outcome after 3 months (P = .017) and a trend toward better outcome after 1 year (P = .083).   CONCLUSIONS: High-dose MgSO4 therapy might be efficient as a prophylactic adjacent therapy after SAH to reduce the risk for poor outcome.  There was no significant difference in mortality rate at discharge (p = 0.328). A trend toward improved outcome as measured by the modifed Rankin Scale (p = 0.084), but not the Glasgow Outcome Scale (p = 1.0), was seen in the MgSO4 treated group. CONCLUSIONS: Analysis of the results suggests that MgSO4 infusion may have a role in cerebral vasospasm prophylaxis if therapy is initiated within 48 hours of aneurysm rupture. There was, however, no difference between groups in functional recovery or Glasgow Outcome Scale score.  Patients receiving MgSO4 tended to have fewer neurological deficits, better functional recovery and an improved score in GOS.  CONCLUSIONS: MgSO4 infusion after aneurysmal SAH is well tolerated and may be useful in producing better outcome. CONCLUSION: Magnesium did not seem to interfere in vasospasm frequency but apparently acted favorably in decreasing morbidity and length of hospital stay. None of the patients died; no CT evidence of ischemic infarction was present; and most had good outcomes (GOS 5 in 10 patients; GOS 4 in 8 patients). At that time, 18 patients in the treatment group and 6 in the placebo group had an excellent outcome (risk ratio, 3.4; 95% CI, 1.3 to 8.9). CONCLUSIONS: This study suggests that magnesium reduces DCI and subsequent poor outcome, but the results are not yet definitive.  We observed a trend in which a higher percentage of patients obtained GOS scores of 4 or 5 in the group treated with MgSO4, but the trend did not reach a statistically significant level.  Magnesium sulfate treatment improves outcome in patients with subarachnoid hemorrhage: a meta-analysis study. BACKGROUND AND PURPOSE: Pilot clinical trials using magnesium sulfate in patients with acute aneurysmal subarachnoid hemorrhage have reported trends toward improvement in clinical outcomes. Preliminary evidence has suggested that magnesium sulfate infusion reduces delayed ischemic neurological deficit and improves clinical outcome after aneurysmal subarachnoid hemorrhage. Our results indicate that although there was reduced likelihood of a poor outcome for patients treated with magnesium sulfate after SAH, patient mortality was not improved. CONCLUSION: Administration of intra-arterial magnesium sulfate in combination with nicardipine was well tolerated in patients with subarachnoid hemorrhage and cerebral vasospasm without a significant change in MAP and ICP. Current evidence does not support the prophylactic use of magnesium sulfate in aneurysmal subarachnoid hemorrhage Preliminary evidence has suggested that magnesium sulfate infusion reduces delayed ischemic neurological deficit and improves clinical outcome after aneurysmal subarachnoid hemorrhage A meta-analysis of current data suggests that magnesium sulfate infusion improves the outcome after aneurysmal subarachnoid hemorrhage through a reduction in delayed ischemic neurological deficit Despite the publication of several randomized controlled studies, there is still much debate on whether magnesium sulfate improves outcome in patients with aneurysmal subarachnoid hemorrhage Magnesium sulphate is a neuroprotective agent that might improve outcome after aneurysmal subarachnoid haemorrhage by reducing the occurrence or improving the outcome of delayed cerebral ischaemia./train.json: 238it [18:02,  2.96s/it]./train.json: 239it [18:04,  2.86s/it]./train.json: 240it [18:07,  2.72s/it]./train.json: 241it [18:09,  2.63s/it]./train.json: 242it [18:12,  2.65s/it]./train.json: 243it [18:14,  2.57s/it]./train.json: 244it [18:17,  2.77s/it]./train.json: 245it [18:21,  2.99s/it]./train.json: 246it [18:25,  3.23s/it]./train.json: 247it [18:28,  3.40s/it]./train.json: 248it [18:32,  3.52s/it]./train.json: 249it [18:36,  3.51s/it]./train.json: 250it [18:39,  3.52s/it]./train.json: 251it [18:43,  3.51s/it]./train.json: 252it [18:47,  3.61s/it]./train.json: 253it [18:51,  3.73s/it]./train.json: 254it [18:54,  3.73s/it]./train.json: 255it [18:58,  3.78s/it]./train.json: 256it [19:02,  3.65s/it]./train.json: 257it [19:05,  3.59s/it]./train.json: 258it [19:08,  3.50s/it]./train.json: 259it [19:12,  3.51s/it]./train.json: 260it [19:15,  3.50s/it]./train.json: 261it [19:19,  3.57s/it]./train.json: 262it [19:23,  3.57s/it]./train.json: 263it [19:27,  3.66s/it]./train.json: 264it [19:30,  3.64s/it]./train.json: 265it [19:35,  3.98s/it]./train.json: 266it [19:38,  3.82s/it]./train.json: 267it [19:42,  3.71s/it]./train.json: 268it [19:46,  3.82s/it]./train.json: 269it [19:50,  3.84s/it]./train.json: 270it [19:54,  3.95s/it]./train.json: 271it [19:58,  3.99s/it]./train.json: 272it [20:01,  3.82s/it]./train.json: 273it [20:05,  3.75s/it]./train.json: 274it [20:09,  3.68s/it]./train.json: 275it [20:12,  3.66s/it]./train.json: 276it [20:16,  3.70s/it]./train.json: 277it [20:23,  4.61s/it]./train.json: 278it [20:26,  4.31s/it]./train.json: 279it [20:29,  3.89s/it]./train.json: 280it [20:33,  3.88s/it]./train.json: 281it [20:37,  3.82s/it]./train.json: 282it [20:41,  3.82s/it]./train.json: 283it [20:44,  3.77s/it]./train.json: 284it [20:48,  3.69s/it]./train.json: 285it [20:51,  3.69s/it]./train.json: 286it [20:56,  3.80s/it]./train.json: 287it [20:59,  3.67s/it]./train.json: 288it [21:02,  3.65s/it]./train.json: 289it [21:06,  3.57s/it]./train.json: 290it [21:09,  3.49s/it]./train.json: 291it [21:13,  3.49s/it]./train.json: 292it [21:16,  3.49s/it]./train.json: 293it [21:20,  3.49s/it]./train.json: 294it [21:23,  3.50s/it]./train.json: 295it [21:27,  3.50s/it]./train.json: 296it [21:30,  3.56s/it]./train.json: 297it [21:34,  3.70s/it]./train.json: 298it [21:38,  3.71s/it]./train.json: 299it [21:42,  3.71s/it]./train.json: 300it [21:45,  3.63s/it]./train.json: 301it [21:49,  3.60s/it]./train.json: 302it [21:52,  3.54s/it]./train.json: 303it [21:56,  3.54s/it]./train.json: 304it [21:59,  3.47s/it]./train.json: 305it [22:03,  3.54s/it]./train.json: 306it [22:06,  3.45s/it]./train.json: 307it [22:10,  3.52s/it]./train.json: 308it [22:13,  3.54s/it]./train.json: 309it [22:17,  3.60s/it]./train.json: 310it [22:20,  3.57s/it]./train.json: 311it [22:24,  3.61s/it]./train.json: 312it [22:28,  3.56s/it]./train.json: 313it [22:31,  3.55s/it]./train.json: 314it [22:35,  3.62s/it]./train.json: 315it [22:38,  3.56s/it]./train.json: 316it [22:42,  3.51s/it]./train.json: 317it [22:45,  3.52s/it]./train.json: 318it [22:49,  3.53s/it]./train.json: 319it [22:52,  3.55s/it]./train.json: 320it [22:56,  3.53s/it]./train.json: 321it [22:59,  3.43s/it]./train.json: 322it [23:03,  3.44s/it]./train.json: 323it [23:06,  3.54s/it]./train.json: 324it [23:10,  3.48s/it]./train.json: 325it [23:13,  3.55s/it]./train.json: 326it [23:17,  3.52s/it]./train.json: 327it [23:20,  3.51s/it]./train.json: 328it [23:24,  3.46s/it]./train.json: 329it [23:27,  3.50s/it]./train.json: 330it [23:31,  3.52s/it]./train.json: 331it [23:34,  3.53s/it]./train.json: 332it [23:38,  3.55s/it]./train.json: 333it [23:41,  3.48s/it]./train.json: 334it [23:46,  3.82s/it]./train.json: 335it [23:50,  3.82s/it]./train.json: 336it [23:53,  3.74s/it]./train.json: 337it [23:57,  3.68s/it]./train.json: 338it [24:01,  3.69s/it]./train.json: 339it [24:04,  3.59s/it]./train.json: 340it [24:08,  3.61s/it]./train.json: 341it [24:11,  3.65s/it]./train.json: 342it [24:15,  3.56s/it]./train.json: 343it [24:18,  3.56s/it]./train.json: 344it [24:22,  3.55s/it]./train.json: 345it [24:25,  3.56s/it]./train.json: 346it [24:29,  3.52s/it]./train.json: 347it [24:32,  3.56s/it]./train.json: 348it [24:36,  3.50s/it]./train.json: 349it [24:39,  3.49s/it]./train.json: 350it [24:43,  3.51s/it]./train.json: 351it [24:46,  3.50s/it]./train.json: 352it [24:50,  3.51s/it]./train.json: 353it [24:53,  3.50s/it]./train.json: 354it [24:57,  3.52s/it]./train.json: 355it [25:00,  3.48s/it]./train.json: 356it [25:04,  3.58s/it]./train.json: 357it [25:08,  3.55s/it]./train.json: 358it [25:11,  3.47s/it]./train.json: 359it [25:14,  3.47s/it]./train.json: 360it [25:18,  3.41s/it]./train.json: 361it [25:21,  3.48s/it]./train.json: 362it [25:25,  3.53s/it]./train.json: 363it [25:28,  3.49s/it]./train.json: 364it [25:32,  3.61s/it]./train.json: 365it [25:36,  3.58s/it]./train.json: 366it [25:39,  3.53s/it]./train.json: 367it [25:43,  3.57s/it]./train.json: 368it [25:46,  3.60s/it]./train.json: 369it [25:50,  3.64s/it]./train.json: 370it [25:54,  3.61s/it]./train.json: 371it [25:59,  4.01s/it]./train.json: 372it [26:02,  3.87s/it]./train.json: 373it [26:05,  3.71s/it]./train.json: 374it [26:09,  3.65s/it]./train.json: 375it [26:13,  3.77s/it]
HTTPSConnectionPool(host='translate.google.com', port=443): Max retries exceeded with url: /m?q=ntegrins+are+heterodimeric+structural+components+of+the+plasma+membrane+whose+ligands+include+a+large+number+of+extracellular+matrix+(ECM)+proteins.++Recently,+integrin+%CE%B1v%CE%B23+has+been+shown+to+have+a+panel+of+previously+unappreciated+small+molecule+receptor+sites+for+thyroid+hormone+and+hormone+analogues,+for+dihydrotestosterone,+and+for+resveratrol,+a+polyphenol+that+has+certain+estrogen-like+features.+The+integrin+receptor+activation+by+T4+may+take+a+role+in+plasma+membrane+processes+involved+in+the+male+reproductive+system.+Rapid+signaling+via+this+plasma+membrane+binding+site+appears+to+be+responsible+for+many+nongenomic+effects+of+thyroid+hormones,+independent+of+the+classic+nuclear+receptors.&tl=zh-CN&sl=en (Caused by SSLError(SSLEOFError(8, 'EOF occurred in violation of protocol (_ssl.c:1131)'))) ntegrins are heterodimeric structural components of the plasma membrane whose ligands include a large number of extracellular matrix (ECM) proteins.  Recently, integrin v3 has been shown to have a panel of previously unappreciated small molecule receptor sites for thyroid hormone and hormone analogues, for dihydrotestosterone, and for resveratrol, a polyphenol that has certain estrogen-like features. The integrin receptor activation by T4 may take a role in plasma membrane processes involved in the male reproductive system. Rapid signaling via this plasma membrane binding site appears to be responsible for many nongenomic effects of thyroid hormones, independent of the classic nuclear receptors.
HTTPSConnectionPool(host='translate.google.com', port=443): Max retries exceeded with url: /m?q=he+etiology+of+subacute+(de+Quervain's)+thyroiditis+(SAT)+is+uncertain,+although+it+probably+represents+a+nonspecific+inflammatory+response+by+the+thyroid+to+a+variety+of+viruses.+Subacute+thyroiditis+is+an+inflammatory+disorder+of+the+thyroid+caused+probably+by+viruses.+I+We+believe+that+the+etiologic+agent+was+the+Epstein-Barr+virus+because+heterophile+and+Epstein-Barr+virus-specific+antibodies+were+positive.+ltogether,+these+results+indicate+that+the+mechanism+of+inhibition+of+Spumavirinae+infection+by+interferon+differs+from+that+described+for+the+other+Retroviridae,+and+particularly+for+types+B,+C+and+D+viruses.+Our+data+is+of+therapeutic+interest+since+Spumavirinae+have+been+linked+to+pathological+processes+such+as+de+Quervain+thyroiditis.&tl=zh-CN&sl=en (Caused by SSLError(SSLEOFError(8, 'EOF occurred in violation of protocol (_ssl.c:1131)'))) he etiology of subacute (de Quervain's) thyroiditis (SAT) is uncertain, although it probably represents a nonspecific inflammatory response by the thyroid to a variety of viruses. Subacute thyroiditis is an inflammatory disorder of the thyroid caused probably by viruses. I We believe that the etiologic agent was the Epstein-Barr virus because heterophile and Epstein-Barr virus-specific antibodies were positive. ltogether, these results indicate that the mechanism of inhibition of Spumavirinae infection by interferon differs from that described for the other Retroviridae, and particularly for types B, C and D viruses. Our data is of therapeutic interest since Spumavirinae have been linked to pathological processes such as de Quervain thyroiditis.
HTTPSConnectionPool(host='translate.google.com', port=443): Max retries exceeded with url: /m?q=Does+resveratrol+reduce+cardiac+remodeling?&tl=zh-CN&sl=en (Caused by SSLError(SSLEOFError(8, 'EOF occurred in violation of protocol (_ssl.c:1131)'))) Does resveratrol reduce cardiac remodeling?
HTTPSConnectionPool(host='translate.google.com', port=443): Max retries exceeded with url: /m?q=In+conclusion,+resveratrol+attenuated+cardiac+oxidative+damage+and+left+ventricular+remodeling+and+enhanced+the+decreased+expression+of+SIRT1+in+hearts+of+old+rats+with+emphysema+and+thus+might+be+a+therapeutic+modality+for+cardiac+injury+complicated+in+chronic+obstructive+pulmonary+disease+(COPD).+In+conclusion,+resveratrol+is+a+beneficial+pharmacological+tool+that+augments+autophagy+to+bring+about+reverse+remodeling+in+the+postinfarction+heart.+Resveratrol+administration+reduced+atrial+CSPC+loss,+succeeded+in+preserving+the+functional+abilities+of+CSPCs+and+mature+cardiac+cells,+improved+cardiac+environment+by+reducing+inflammatory+state+and+decreased+unfavorable+ventricular+remodeling+of+the+diabetic+heart,+leading+to+a+marked+recovery+of+ventricular+function.+These+findings+indicate+that+RSV+can+constitute+an+adjuvant+therapeutic+option+in+DCM+prevention.&tl=zh-CN&sl=en (Caused by SSLError(SSLEOFError(8, 'EOF occurred in violation of protocol (_ssl.c:1131)'))) In conclusion, resveratrol attenuated cardiac oxidative damage and left ventricular remodeling and enhanced the decreased expression of SIRT1 in hearts of old rats with emphysema and thus might be a therapeutic modality for cardiac injury complicated in chronic obstructive pulmonary disease (COPD). In conclusion, resveratrol is a beneficial pharmacological tool that augments autophagy to bring about reverse remodeling in the postinfarction heart. Resveratrol administration reduced atrial CSPC loss, succeeded in preserving the functional abilities of CSPCs and mature cardiac cells, improved cardiac environment by reducing inflammatory state and decreased unfavorable ventricular remodeling of the diabetic heart, leading to a marked recovery of ventricular function. These findings indicate that RSV can constitute an adjuvant therapeutic option in DCM prevention.
HTTPSConnectionPool(host='translate.google.com', port=443): Max retries exceeded with url: /m?q=HuR+and+TIA1/TIAL1+are+involved+in+regulation+of+alternative+splicing+of+SIRT1+pre-mRNA+Here+we+describe+experiments+showing+that+HuR+and+TIA1/TIAL1,+two+kinds+of+RNA-binding+proteins,+were+involved+in+the+regulation+of+alternative+splicing+of+SIRT1+pre-mRNA+under+normal+and+stress+circumstances+HuR+increased+SIRT1-%E2%88%86Exon8+by+promoting+SIRT1+exon+8+exclusion,+whereas+TIA1/TIAL1+inhibition+of+the+exon+8+exclusion+led+to+a+decrease+in+SIRT1-%E2%88%86Exon8+mRNA+levels.++HuR+regulates+alternative+splicing+of+the+TRA2%CE%B2+gene+in+human+colon+cancer+cells+under+oxidative+stress+Hu+antigen+R+(HuR)+regulates+stress+responses+through+stabilizing+and/or+facilitating+the+translation+of+target+mRNAs+We+show+here+that+the+RBP+embryonic+lethal+abnormal+vision+like+1+(ELAVL1,+also+know+as+HuR)+regulates+the+alternative+splicing+of+eukaryotic+translation+initiation+factor+4E+nuclear+import+factor+1+(Eif4enif1),+which+encodes+an+eukaryotic+translation+initiation+factor+4E+transporter+(4E-T)+protein+and+suppresses+the+expression+of+capped+mRNAs+Further,+endothelial-specific+Elavl1+knockout+mice+exhibited+reduced+revascularization+after+hind+limb+ischemia+and+tumor+angiogenesis+in+oncogene-induced+mammary+cancer,+resulting+in+attenuated+blood+flow+and+tumor+growth,+respectively.++Changes+in+cellular+mRNA+stability,+splicing,+and+polyadenylation+through+HuR+protein+sequestration+by+a+cytoplasmic+RNA+virus+Furthermore,+significant+changes+can+be+observed+in+nuclear+alternative+polyadenylation+and+splicing+events+on+cellular+pre-mRNAs+as+a+result+of+sequestration+of+HuR+protein+by+the+3'+UTR+of+transcripts+of+this+cytoplasmic+RNA+virus.+Here+we+demonstrate+that+expression+of+2A(pro)+induces+a+selective+nucleo-cytoplasm+translocation+of+several+important+RNA+binding+proteins+and+splicing+factors.+Subcellular+fractionation+studies,+together+with+immunofluorescence+microscopy+revealed+an+asymmetric+distribution+of+HuR+and+TIA1/TIAR+in+2A(pro)+expressing+cells,+which+modulates+splicing+of+the+human+Fas+exon+6+knockdown+of+HuR+or+overexpression+of+TIA1/TIAR,+leads+to+Fas+exon+6+inclusion+in+2A(pro)-expressing+cells+The+differential+expression+levels+of+T-cell+intracellular+antigens+(TIA)+and+Hu+antigen+R+(HuR)+are+concomitant+with+a+splicing+switch+in+apoptosis+receptor+Fas+in+HCT-116+cells+overexpression+and+knockdown+of+HuR+led+to+Fas+exon+6+skipping+and+inclusion,+respectively.+These+results+suggest+that+the+TIA+and+HuR+cellular+ratio+influences+cell-type+specific+Fas+exon+6+splicing+pattern.+Hu+antigen+R+(HuR)+functions+as+an+alternative+pre-mRNA+splicing+regulator+of+Fas+apoptosis-promoting+receptor+on+exon+definition+antiapoptotic+regulator+Hu+antigen+R+(HuR,+ELAVL1),+a+member+of+the+embryonic+lethal,+abnormal+vision,+Drosophila-like+(ELAVL)+family,+promotes+Fas+exon+6+skipping+by+binding+to+an+exonic+splicing+silencer+ELAV/Hu+proteins+bind+to+AU-rich+elements+(ARE)+in+mRNAs+and+regulate+their+stability+from+splicing+to+translation,+and+the+ubiquitous+HuR+protein+has+been+implicated+in+cancerous+cell+growth.+The+HuR+protein+regulates+the+expression+of+thousands+of+cellular+transcripts+by+modulating+mRNA+splicing,+trafficking,+translation,+and+stability.+Hu+antigen+R+(HuR)+functions+as+an+alternative+pre-mRNA+splicing+regulator+of+Fas+apoptosis-promoting+receptor+on+exon+definition.+I+report+that+antiapoptotic+regulator+Hu+antigen+R+(HuR,+ELAVL1),+a+member+of+the+embryonic+lethal,+abnormal+vision,+Drosophila-like+(ELAVL)+family,+promotes+Fas+exon+6+skipping+by+binding+to+an+exonic+splicing+silencer.++Changes+in+cellular+mRNA+stability,+splicing,+and+polyadenylation+through+HuR+protein+sequestration+by+a+cytoplasmic+RNA+virus.+Further,+the+silencing+capacity+of+HuR+as+splicing+regulator+resides+in+the+RRM1+and+hinge-RRM3+domains.++HuR+and+TIA1/TIAL1+are+involved+in+regulation+of+alternative+splicing+of+SIRT1+pre-mRNA.+HuR+regulates+alternative+splicing+of+the+TRA2%CE%B2+gene+in+human+colon+cancer+cells+under+oxidative+stress.+The+HuR+protein+regulates+the+expression+of+thousands+of+cellular+transcripts+by+modulating+mRNA+splicing,+trafficking,+translation,+and+stability.++Further,+the+silencing+capacity+of+HuR+as+splicing+regulator+resides+in+the+RRM1+and+hinge-RRM3+domains.+Taken+together,+these+results+support+a+functional+link+between+HuR+as+repressor+of+alternative+Fas+splicing+and+the+molecular+mechanisms+modulating+programmed+cell+death.+We+are+interested+in+interactions+involving+hnRNP+proteins+participating+in+several+steps+of+mRNA+processing+(mainly+pre-mRNA+splicing)+and+HuR+with+an+established+role+in+stability/translation+of+associated+mRNAs.+hnRNP+and+HuR+proteins+have+a+major+nucleoplasmic+localization+and+ability+to+shuttle+between+nucleus+and+cytoplasm.+We+report+here+on+interactions+between+hnRNP+and+HuR+proteins+that+were+identified+in+the+context+of+isolated+hnRNP+and+mRNP+complexes.++Despite+the+fact+that+HuR+sites+are+observed+in+intronic+regions,+our+data+do+not+support+a+role+for+HuR+in+regulating+splicing.&tl=zh-CN&sl=en (Caused by ProxyError('Cannot connect to proxy.', ConnectionResetError(104, 'Connection reset by peer'))) ./train.json: 376it [26:16,  3.55s/it]./train.json: 377it [26:20,  3.61s/it]./train.json: 378it [26:24,  3.71s/it]./train.json: 379it [26:28,  3.74s/it]./train.json: 380it [26:31,  3.79s/it]./train.json: 381it [26:35,  3.81s/it]./train.json: 382it [26:39,  3.74s/it]./train.json: 383it [26:43,  3.80s/it]./train.json: 384it [26:47,  3.83s/it]./train.json: 385it [26:51,  3.87s/it]./train.json: 386it [26:54,  3.84s/it]./train.json: 387it [26:59,  4.00s/it]./train.json: 388it [27:02,  3.63s/it]./train.json: 389it [27:05,  3.61s/it]./train.json: 390it [27:09,  3.70s/it]./train.json: 391it [27:12,  3.55s/it]./train.json: 392it [27:16,  3.45s/it]./train.json: 393it [27:19,  3.55s/it]./train.json: 394it [27:23,  3.54s/it]./train.json: 395it [27:26,  3.48s/it]./train.json: 396it [27:30,  3.51s/it]./train.json: 397it [27:33,  3.45s/it]./train.json: 398it [27:35,  3.13s/it]HuR and TIA1/TIAL1 are involved in regulation of alternative splicing of SIRT1 pre-mRNA Here we describe experiments showing that HuR and TIA1/TIAL1, two kinds of RNA-binding proteins, were involved in the regulation of alternative splicing of SIRT1 pre-mRNA under normal and stress circumstances HuR increased SIRT1-Exon8 by promoting SIRT1 exon 8 exclusion, whereas TIA1/TIAL1 inhibition of the exon 8 exclusion led to a decrease in SIRT1-Exon8 mRNA levels.  HuR regulates alternative splicing of the TRA2 gene in human colon cancer cells under oxidative stress Hu antigen R (HuR) regulates stress responses through stabilizing and/or facilitating the translation of target mRNAs We show here that the RBP embryonic lethal abnormal vision like 1 (ELAVL1, also know as HuR) regulates the alternative splicing of eukaryotic translation initiation factor 4E nuclear import factor 1 (Eif4enif1), which encodes an eukaryotic translation initiation factor 4E transporter (4E-T) protein and suppresses the expression of capped mRNAs Further, endothelial-specific Elavl1 knockout mice exhibited reduced revascularization after hind limb ischemia and tumor angiogenesis in oncogene-induced mammary cancer, resulting in attenuated blood flow and tumor growth, respectively.  Changes in cellular mRNA stability, splicing, and polyadenylation through HuR protein sequestration by a cytoplasmic RNA virus Furthermore, significant changes can be observed in nuclear alternative polyadenylation and splicing events on cellular pre-mRNAs as a result of sequestration of HuR protein by the 3' UTR of transcripts of this cytoplasmic RNA virus. Here we demonstrate that expression of 2A(pro) induces a selective nucleo-cytoplasm translocation of several important RNA binding proteins and splicing factors. Subcellular fractionation studies, together with immunofluorescence microscopy revealed an asymmetric distribution of HuR and TIA1/TIAR in 2A(pro) expressing cells, which modulates splicing of the human Fas exon 6 knockdown of HuR or overexpression of TIA1/TIAR, leads to Fas exon 6 inclusion in 2A(pro)-expressing cells The differential expression levels of T-cell intracellular antigens (TIA) and Hu antigen R (HuR) are concomitant with a splicing switch in apoptosis receptor Fas in HCT-116 cells overexpression and knockdown of HuR led to Fas exon 6 skipping and inclusion, respectively. These results suggest that the TIA and HuR cellular ratio influences cell-type specific Fas exon 6 splicing pattern. Hu antigen R (HuR) functions as an alternative pre-mRNA splicing regulator of Fas apoptosis-promoting receptor on exon definition antiapoptotic regulator Hu antigen R (HuR, ELAVL1), a member of the embryonic lethal, abnormal vision, Drosophila-like (ELAVL) family, promotes Fas exon 6 skipping by binding to an exonic splicing silencer ELAV/Hu proteins bind to AU-rich elements (ARE) in mRNAs and regulate their stability from splicing to translation, and the ubiquitous HuR protein has been implicated in cancerous cell growth. The HuR protein regulates the expression of thousands of cellular transcripts by modulating mRNA splicing, trafficking, translation, and stability. Hu antigen R (HuR) functions as an alternative pre-mRNA splicing regulator of Fas apoptosis-promoting receptor on exon definition. I report that antiapoptotic regulator Hu antigen R (HuR, ELAVL1), a member of the embryonic lethal, abnormal vision, Drosophila-like (ELAVL) family, promotes Fas exon 6 skipping by binding to an exonic splicing silencer.  Changes in cellular mRNA stability, splicing, and polyadenylation through HuR protein sequestration by a cytoplasmic RNA virus. Further, the silencing capacity of HuR as splicing regulator resides in the RRM1 and hinge-RRM3 domains.  HuR and TIA1/TIAL1 are involved in regulation of alternative splicing of SIRT1 pre-mRNA. HuR regulates alternative splicing of the TRA2 gene in human colon cancer cells under oxidative stress. The HuR protein regulates the expression of thousands of cellular transcripts by modulating mRNA splicing, trafficking, translation, and stability.  Further, the silencing capacity of HuR as splicing regulator resides in the RRM1 and hinge-RRM3 domains. Taken together, these results support a functional link between HuR as repressor of alternative Fas splicing and the molecular mechanisms modulating programmed cell death. We are interested in interactions involving hnRNP proteins participating in several steps of mRNA processing (mainly pre-mRNA splicing) and HuR with an established role in stability/translation of associated mRNAs. hnRNP and HuR proteins have a major nucleoplasmic localization and ability to shuttle between nucleus and cytoplasm. We report here on interactions between hnRNP and HuR proteins that were identified in the context of isolated hnRNP and mRNP complexes.  Despite the fact that HuR sites are observed in intronic regions, our data do not support a role for HuR in regulating splicing.
HTTPSConnectionPool(host='translate.google.com', port=443): Max retries exceeded with url: /m?q=Is+there+any+data+to+suggest+that+TRH+(thyrotropin+releasing+hormone)+administration+can+improve+symptom+severity+of+amyotrophic+lateral+sclerosis+patients?&tl=zh-CN&sl=en (Caused by ProxyError('Cannot connect to proxy.', ConnectionResetError(104, 'Connection reset by peer'))) Is there any data to suggest that TRH (thyrotropin releasing hormone) administration can improve symptom severity of amyotrophic lateral sclerosis patients?
HTTPSConnectionPool(host='translate.google.com', port=443): Max retries exceeded with url: /m?q=Can+siRNA+affect+response+to+afatinib+treatment?&tl=zh-CN&sl=en (Caused by SSLError(SSLEOFError(8, 'EOF occurred in violation of protocol (_ssl.c:1131)'))) Can siRNA affect response to afatinib treatment?
HTTPSConnectionPool(host='translate.google.com', port=443): Max retries exceeded with url: /m?q=Are+immune+cells+affected+in+Amyotrophic+Lateral+Sclerosis?&tl=zh-CN&sl=en (Caused by ProxyError('Cannot connect to proxy.', ConnectionResetError(104, 'Connection reset by peer'))) Are immune cells affected in Amyotrophic Lateral Sclerosis?
HTTPSConnectionPool(host='translate.google.com', port=443): Max retries exceeded with url: /m?q=Is+Rac1+involved+in+cancer+cell+invasion?&tl=zh-CN&sl=en (Caused by ProxyError('Cannot connect to proxy.', ConnectionResetError(104, 'Connection reset by peer'))) Is Rac1 involved in cancer cell invasion?
HTTPSConnectionPool(host='translate.google.com', port=443): Max retries exceeded with url: /m?q=In+the+Matrigel+invasion+assay,+knockdown+of+CCR1+and+inhibition+of+the+ERK+and+Rac+signaling+pathways+significantly+decreased+the+number+of+invading+cells.+These+results+demonstrated+for+the+first+time+that+the+interaction+of+CCR1+with+CCL5+caused+by+increased+expression+of+CCR1+promotes+invasion+of+PC3PR+cells+by+increasing+secretion+of+MMPs+2+and+9+and+by+activating+ERK+and+Rac+signaling.+These+data+suggest+that+P-Rex1+has+an+influence+on+physiological+migratory+processes,+such+as+invasion+of+cancer+cells,+both+through+effects+upon+classical+Rac1-driven+motility+and+a+novel+association+with+RTK+signalling+complexes.+Activated+PAR1+induced+RhoA+and+Rac1+phosphorylation,+and+subsequent+overexpression+of+myosin+IIA+and+filamin+B+which+are+stress+fiber+components+that+were+identified+by+PMF+analysis+of+peptide+mass+data+obtained+by+MALDI-TOF/MS+measurement.++These+results+demonstrate+that+PAR1+activation+induces+cell+morphological+change+associated+with+cell+motility+via+Rho+family+activation+and+cytoskeletal+protein+overexpression,+and+has+a+critical+role+in+gastric+cancer+cell+invasion+and+metastasis.+Rac1+was+found+to+be+required+for+actopaxin-induced+matrix+degradation+whereas+inhibition+of+myosin+contractility+promoted+degradation+in+the+phosphomutant-expressing+Quint+cells,+indicating+that+a+balance+of+Rho+GTPase+signaling+and+regulation+of+cellular+tension+are+important+for+the+process.+Taken+together,+this+study+demonstrates+a+new+role+for+actopaxin+phosphorylation+in+matrix+degradation+and+cell+invasion+via+regulation+of+Rho+GTPase+signaling.+BART+inhibits+pancreatic+cancer+cell+invasion+by+Rac1+inactivation+through+direct+binding+to+active+Rac1+We+report+that+Binder+of+Arl+Two+(BART)+plays+a+role+in+inhibiting+cell+invasion+by+regulating+the+activity+of+the+Rho+small+guanosine+triphosphatase+protein+Rac1+in+pancreatic+cancer+cells.+BART+interacts+with+active+forms+of+Rac1,+and+the+BART-Rac1+complex+localizes+at+the+leading+edges+of+migrating+cancer+cells.+Suppression+of+BART+increases+active+Rac1,+thereby+increasing+cell+invasion.+Treatment+of+pancreatic+cancer+cells+in+which+BART+is+stably+knocked+down+with+a+Rac1+inhibitor+decreases+invasiveness.+Thus,+BART-dependent+inhibition+of+cell+invasion+is+likely+associated+with+decreased+active+Rac1.+The+Rac1+inhibitor+inhibits+the+lamellipodia+formation+that+is+stimulated+by+suppression+of+BART.+Our+results+imply+that+BART+regulates+actin-cytoskeleton+rearrangements+at+membrane+ruffles+through+modulation+of+the+activity+of+Rac1,+which,+in+turn,+inhibits+pancreatic+cancer+cell+invasion.+It+has+been+reported+as+an+important+inducer+of+cancer+cell+migration+and+invasion,+with+underlying+molecular+mechanisms+involving+the+signalling+mediated+by+its+juxtamembrane+domain,+the+secretion+of+matrix+metalloproteases+to+the+extracellular+media,+and+the+cleavage+of+a+P-cadherin+soluble+form+with+pro-invasive+activity.+Intracellularly,+this+protein+interferes+with+the+endogenous+cadherin/catenin+complex,+inducing+p120-catenin+delocalization+to+the+cytoplasm,+and+the+consequent+activation+of+Rac1/Cdc42+and+associated+alterations+in+the+actin+cytoskeleton.+Targeted+down-regulation+of+RhoC+led+to+sustained+activation+of+Rac1+GTPase+and+morphological,+molecular+and+phenotypic+changes+reminiscent+of+epithelial+to+mesenchymal+transition.+We+also+find+that+Rac1+GTPase+mediates+tight+binding+of+prostate+cancer+cells+to+bone+marrow+endothelial+cells+and+promotes+retraction+of+endothelial+cells+required+for+tumor+cell+diapedesis.+Finally,+Rac1+leads+to+%CE%B21+integrin+activation,+suggesting+a+mechanism+that+Rac1+can+mediate+tight+binding+with+endothelial+cells.+Together,+our+data+suggest+that+Rac1+GTPase+is+key+mediator+of+prostate+cancer+cell-bone+marrow+endothelial+cell+interactions.+Furthermore,+expression+of+dominant-negative+Rac1+(T17N)+could+largely+block+EGF-induced+PI3K/Akt-PAK1+activation+and+cell+migration.+Our+study+demonstrated+that+EGF-induced+cell+migration+involves+a+cascade+of+signalling+events,+including+activation+of+Rac1,+generation+of+ROS+and+subsequent+activation+of+PI3K/Akt+and+PAK1.+Small+GTPase+proteins,+including+RhoA,+RhoB,+RhoC,+Rac1,+and+cdc42,+are+important+molecules+for+linking+cell+shape+and+cell-cycle+progression+because+of+their+role+in+both+cytoskeletal+arrangements+and+mitogenic+signaling.+The+suppression+of+MMP-2+expression+by+CTXG+led+to+an+inhibition+of+SW620+cells+invasion+and+migration+by+inactivating+Rac1+and+Cdc42+but+not+RhoA+GTPase.+In+conclusion,+our+data+demonstrate+that+CTXG+exerted+anti-invasion+action+in+SW620+cells+by+targeting+MMP-2+though+regulating+the+activities+of+Rac1,+Cdc42+and+their+downstream+transcriptional+factor+AP-1.+ctivation+of+H-Ras+and+Rac1+correlates+with+epidermal+growth+factor-induced+invasion+in+Hs578T+and+MDA-MB-231+breast+carcinoma+cells+We+have+previously+shown+that+H-Ras,+but+not+N-Ras,+induces+an+invasive+phenotype+mediated+by+small+GTPase+Rac1+in+MCF10A+human+breast+epithelial+cells.+Moreover,+siRNA-knockdown+of+Rac1+significantly+inhibited+the+EGF-induced+invasiveness+in+these+cells.+Our+data+demonstrate+that+the+activation+of+H-Ras+and+the+downstream+molecule+Rac1+correlates+with+EGF-induced+breast+cancer+cell+invasion,+providing+important+information+on+the+regulation+of+malignant+progression+in+mammary+carcinoma+cells.+At+50%25+growth-inhibiting+concentration,+icariin+significantly+suppressed+tumor+cells+migration+and+invasion,+which+were+traceable+to+down-regulation+of+Rac1+and+VASP.++These+results+indicate+that+icariin+exerts+negative+effects+on+tumor+cell+invasion+and+migration+via+the+Rac1-dependent+VASP+pathway+and+may+be+a+potential+anti-cancer+drug.+RhoGDI2+modulates+the+invasiveness+and+metastatic+ability+of+cancer+cells+through+regulation+of+Rac1+activity.+We+also+showed+that+GBM+cells+secrete+Sema3A+endogenously,+and+RNA+interference-mediated+downregulation+of+Sema3A+inhibits+migration+and+alters+cell+morphology+that+is+dependent+on+Rac1+activity.+LMO1+and+Dock180,+a+bipartite+Rac1+guanine+nucleotide+exchange+factor,+promote+human+glioma+cell+invasion+Here,+we+report+for+the+first+time+that+engulfment+and+cell+motility+1+(ELMO1)+and+dedicator+of+cytokinesis+1+(Dock180),+a+bipartite+Rac1+guanine+nucleotide+exchange+factor+(GEF),+are+evidently+linked+to+the+invasive+phenotype+of+glioma+cells.+Inhibition+of+endogenous+ELMO1+and+Dock180+expression+significantly+impeded+glioma+cell+invasion+in+vitro+and+in+brain+tissue+slices+with+a+concomitant+reduction+in+Rac1+activation.+Members+of+the+Rac+family+of+small+GTPases+are+known+to+act+as+regulators+of+actin+cytoskeletal+structures+and+strongly+influence+the+cellular+processes+of+integrin-mediated+adhesion+and+migration.+Even+though+hyperactivated+Rac+proteins+have+been+shown+to+influence+metastatic+processes,+these+proteins+have+never+been+directly+linked+to+metastatic+progression.++We+show+that+increased+activation+of+Rac+proteins+directly+correlates+with+increasing+metastatic+potential+in+a+panel+of+cell+variants+derived+from+a+single+metastatic+breast+cancer+cell+line+(MDA-MB-435).+Expression+of+a+dominant+active+Rac1+or+a+dominant+active+Rac3+resulted+in+a+more+invasive+and+motile+phenotype.+Moreover,+expression+of+either+dominant+negative+Rac1+or+dominant+negative+Rac3+into+the+most+metastatic+cell+variant+resulted+in+decreased+invasive+and+motile+properties.+This+study+correlates+endogenous+Rac+activity+with+high+metastatic+potential+and+implicates+Rac+in+the+regulation+of+cell+migration+and+invasion+in+metastatic+breast+cancer+cells.+Taken+together,+these+results+suggest+a+role+for+both+the+Rac1+and+Rac3+GTPases+in+human+breast+cancer+progression.&tl=zh-CN&sl=en (Caused by ProxyError('Cannot connect to proxy.', RemoteDisconnected('Remote end closed connection without response'))) ./train.json: 399it [27:38,  3.09s/it]./train.json: 400it [27:42,  3.20s/it]./train.json: 401it [27:46,  3.45s/it]./train.json: 402it [27:50,  3.51s/it]./train.json: 403it [27:53,  3.52s/it]./train.json: 404it [27:57,  3.53s/it]./train.json: 405it [28:00,  3.54s/it]./train.json: 406it [28:04,  3.67s/it]./train.json: 407it [28:08,  3.71s/it]./train.json: 408it [28:12,  3.74s/it]./train.json: 409it [28:15,  3.66s/it]./train.json: 410it [28:19,  3.65s/it]./train.json: 411it [28:22,  3.56s/it]./train.json: 412it [28:25,  3.45s/it]./train.json: 413it [28:29,  3.54s/it]./train.json: 414it [28:33,  3.63s/it]./train.json: 415it [28:37,  3.78s/it]./train.json: 416it [28:41,  3.86s/it]./train.json: 417it [28:47,  4.30s/it]./train.json: 418it [28:50,  4.11s/it]./train.json: 419it [28:54,  4.06s/it]./train.json: 420it [28:58,  3.95s/it]./train.json: 421it [29:01,  3.85s/it]./train.json: 422it [29:05,  3.70s/it]./train.json: 423it [29:08,  3.67s/it]./train.json: 424it [29:12,  3.61s/it]./train.json: 425it [29:15,  3.61s/it]./train.json: 426it [29:19,  3.54s/it]./train.json: 427it [29:22,  3.52s/it]./train.json: 428it [29:26,  3.46s/it]./train.json: 429it [29:29,  3.46s/it]./train.json: 430it [29:33,  3.62s/it]./train.json: 431it [29:37,  3.59s/it]./train.json: 432it [29:41,  3.77s/it]./train.json: 433it [29:45,  3.75s/it]./train.json: 434it [29:48,  3.65s/it]./train.json: 435it [29:52,  3.64s/it]./train.json: 436it [29:55,  3.67s/it]./train.json: 437it [29:59,  3.71s/it]./train.json: 438it [30:03,  3.67s/it]./train.json: 439it [30:06,  3.67s/it]./train.json: 440it [30:10,  3.62s/it]./train.json: 441it [30:13,  3.46s/it]./train.json: 442it [30:16,  3.48s/it]./train.json: 443it [30:20,  3.52s/it]./train.json: 444it [30:24,  3.53s/it]./train.json: 445it [30:27,  3.55s/it]./train.json: 446it [30:31,  3.60s/it]./train.json: 447it [30:35,  3.69s/it]./train.json: 448it [30:38,  3.66s/it]./train.json: 449it [30:42,  3.65s/it]./train.json: 450it [30:46,  3.68s/it]./train.json: 451it [30:50,  3.72s/it]./train.json: 452it [30:53,  3.69s/it]./train.json: 453it [30:57,  3.65s/it]./train.json: 454it [31:00,  3.64s/it]./train.json: 455it [31:04,  3.62s/it]./train.json: 456it [31:08,  3.68s/it]./train.json: 457it [31:12,  3.75s/it]./train.json: 458it [31:15,  3.68s/it]./train.json: 459it [31:19,  3.57s/it]./train.json: 460it [31:22,  3.56s/it]./train.json: 461it [31:26,  3.57s/it]./train.json: 462it [31:30,  3.74s/it]./train.json: 463it [31:34,  3.90s/it]./train.json: 464it [31:38,  3.86s/it]./train.json: 465it [31:42,  3.94s/it]./train.json: 466it [31:45,  3.75s/it]./train.json: 467it [31:49,  3.70s/it]./train.json: 468it [31:52,  3.60s/it]./train.json: 469it [31:56,  3.70s/it]./train.json: 470it [32:02,  4.34s/it]./train.json: 471it [32:05,  4.02s/it]./train.json: 472it [32:09,  3.82s/it]./train.json: 473it [32:13,  4.01s/it]./train.json: 474it [32:17,  3.88s/it]./train.json: 475it [32:21,  3.90s/it]./train.json: 476it [32:25,  3.90s/it]./train.json: 477it [32:28,  3.80s/it]./train.json: 478it [32:32,  3.94s/it]./train.json: 479it [32:36,  3.85s/it]./train.json: 480it [32:39,  3.68s/it]./train.json: 481it [32:43,  3.58s/it]./train.json: 482it [32:47,  3.69s/it]./train.json: 483it [32:50,  3.63s/it]./train.json: 484it [32:55,  3.94s/it]./train.json: 485it [32:58,  3.83s/it]./train.json: 486it [33:03,  4.10s/it]./train.json: 487it [33:07,  4.03s/it]./train.json: 488it [33:11,  4.06s/it]./train.json: 489it [33:15,  4.06s/it]./train.json: 490it [33:20,  4.29s/it]./train.json: 491it [33:24,  4.33s/it]./train.json: 492it [33:28,  4.20s/it]./train.json: 493it [33:32,  4.10s/it]./train.json: 494it [33:37,  4.35s/it]./train.json: 495it [33:40,  4.04s/it]./train.json: 496it [33:47,  4.85s/it]./train.json: 497it [33:52,  4.79s/it]./train.json: 498it [33:55,  4.40s/it]./train.json: 499it [34:00,  4.57s/it]./train.json: 500it [34:06,  5.05s/it]./train.json: 501it [34:10,  4.72s/it]./train.json: 502it [34:15,  4.62s/it]./train.json: 503it [34:19,  4.55s/it]./train.json: 504it [34:25,  4.93s/it]./train.json: 505it [34:31,  5.35s/it]./train.json: 506it [34:37,  5.40s/it]./train.json: 507it [34:42,  5.22s/it]./train.json: 508it [34:46,  4.88s/it]./train.json: 509it [34:51,  5.06s/it]./train.json: 510it [34:55,  4.57s/it]./train.json: 511it [34:59,  4.44s/it]./train.json: 512it [35:03,  4.55s/it]./train.json: 513it [35:09,  4.89s/it]./train.json: 514it [35:16,  5.43s/it]./train.json: 515it [35:22,  5.67s/it]./train.json: 516it [35:27,  5.40s/it]./train.json: 517it [35:31,  4.89s/it]./train.json: 518it [35:34,  4.60s/it]./train.json: 519it [35:41,  5.19s/it]./train.json: 520it [35:46,  5.16s/it]./train.json: 521it [35:51,  5.15s/it]./train.json: 522it [35:55,  4.85s/it]./train.json: 523it [36:00,  4.77s/it]./train.json: 524it [36:06,  5.04s/it]./train.json: 525it [36:11,  5.09s/it]./train.json: 526it [36:15,  4.71s/it]./train.json: 527it [36:18,  4.36s/it]./train.json: 528it [36:22,  4.18s/it]./train.json: 529it [36:26,  4.25s/it]./train.json: 530it [36:31,  4.48s/it]./train.json: 531it [36:36,  4.39s/it]./train.json: 532it [36:40,  4.33s/it]./train.json: 533it [36:45,  4.67s/it]./train.json: 534it [36:49,  4.53s/it]./train.json: 535it [36:54,  4.55s/it]./train.json: 536it [36:58,  4.39s/it]./train.json: 537it [37:03,  4.44s/it]./train.json: 538it [37:06,  4.11s/it]./train.json: 539it [37:13,  4.92s/it]./train.json: 540it [37:19,  5.30s/it]./train.json: 541it [37:24,  5.26s/it]./train.json: 542it [37:29,  5.15s/it]./train.json: 543it [37:33,  4.73s/it]./train.json: 544it [37:36,  4.36s/it]./train.json: 545it [37:41,  4.41s/it]./train.json: 546it [37:48,  5.12s/it]./train.json: 547it [37:55,  5.69s/it]./train.json: 548it [38:00,  5.53s/it]./train.json: 549it [38:06,  5.61s/it]./train.json: 550it [38:10,  5.35s/it]./train.json: 551it [38:15,  5.23s/it]./train.json: 552it [38:20,  5.08s/it]./train.json: 553it [38:26,  5.41s/it]./train.json: 554it [38:31,  5.26s/it]./train.json: 555it [38:36,  5.31s/it]./train.json: 556it [38:42,  5.41s/it]./train.json: 557it [38:47,  5.27s/it]./train.json: 558it [38:51,  4.98s/it]./train.json: 559it [38:55,  4.54s/it]./train.json: 560it [39:00,  4.62s/it]./train.json: 561it [39:04,  4.67s/it]./train.json: 562it [39:10,  4.78s/it]./train.json: 563it [39:15,  5.13s/it]./train.json: 564it [39:22,  5.53s/it]./train.json: 565it [39:26,  5.19s/it]./train.json: 566it [39:31,  5.11s/it]./train.json: 567it [39:35,  4.76s/it]./train.json: 568it [39:41,  5.04s/it]./train.json: 569it [39:48,  5.56s/it]./train.json: 570it [39:52,  5.20s/it]./train.json: 571it [39:57,  5.08s/it]./train.json: 572it [40:01,  4.82s/it]./train.json: 573it [40:06,  4.82s/it]./train.json: 574it [40:10,  4.75s/it]./train.json: 575it [40:17,  5.23s/it]./train.json: 576it [40:23,  5.43s/it]./train.json: 577it [40:29,  5.75s/it]./train.json: 578it [40:33,  5.33s/it]./train.json: 579it [40:38,  5.20s/it]./train.json: 580it [40:44,  5.45s/it]./train.json: 581it [40:50,  5.45s/it]./train.json: 582it [40:55,  5.48s/it]./train.json: 583it [41:03,  6.01s/it]./train.json: 584it [41:08,  5.82s/it]./train.json: 585it [41:12,  5.22s/it]./train.json: 586it [41:18,  5.48s/it]./train.json: 587it [41:23,  5.34s/it]./train.json: 588it [41:28,  5.23s/it]./train.json: 589it [41:33,  5.21s/it]./train.json: 590it [41:39,  5.51s/it]./train.json: 591it [41:44,  5.28s/it]./train.json: 592it [41:50,  5.52s/it]./train.json: 593it [41:54,  5.00s/it]./train.json: 594it [41:58,  4.71s/it]./train.json: 595it [42:01,  4.32s/it]./train.json: 596it [42:05,  4.16s/it]./train.json: 597it [42:10,  4.49s/it]./train.json: 598it [42:17,  5.01s/it]./train.json: 599it [42:22,  5.14s/it]./train.json: 600it [42:26,  4.73s/it]./train.json: 601it [42:30,  4.67s/it]./train.json: 602it [42:35,  4.73s/it]./train.json: 603it [42:40,  4.82s/it]./train.json: 604it [42:44,  4.58s/it]./train.json: 605it [42:50,  4.83s/it]./train.json: 606it [42:54,  4.56s/it]./train.json: 607it [42:59,  4.81s/it]./train.json: 608it [43:05,  5.10s/it]./train.json: 609it [43:14,  6.29s/it]./train.json: 610it [43:18,  5.70s/it]./train.json: 611it [43:22,  5.23s/it]./train.json: 612it [43:27,  5.01s/it]./train.json: 613it [43:31,  4.80s/it]./train.json: 614it [43:37,  5.03s/it]./train.json: 615it [43:42,  5.02s/it]./train.json: 616it [43:48,  5.39s/it]./train.json: 617it [43:55,  5.84s/it]./train.json: 618it [43:59,  5.28s/it]./train.json: 619it [44:06,  5.92s/it]./train.json: 620it [44:11,  5.71s/it]./train.json: 621it [44:17,  5.60s/it]./train.json: 622it [44:22,  5.57s/it]./train.json: 623it [44:28,  5.60s/it]./train.json: 624it [44:35,  5.98s/it]./train.json: 625it [44:39,  5.51s/it]./train.json: 626it [44:43,  5.10s/it]./train.json: 627it [44:48,  4.81s/it]./train.json: 628it [44:53,  4.91s/it]./train.json: 629it [44:59,  5.30s/it]./train.json: 630it [45:04,  5.12s/it]./train.json: 631it [45:08,  4.89s/it]./train.json: 632it [45:14,  5.22s/it]./train.json: 633it [45:24,  6.58s/it]./train.json: 634it [45:28,  5.85s/it]./train.json: 635it [45:31,  5.16s/it]./train.json: 636it [45:36,  5.00s/it]./train.json: 637it [45:41,  5.01s/it]./train.json: 638it [45:47,  5.25s/it]./train.json: 639it [45:52,  5.22s/it]./train.json: 640it [45:59,  5.60s/it]./train.json: 641it [46:04,  5.67s/it]./train.json: 642it [46:09,  5.22s/it]./train.json: 643it [46:12,  4.81s/it]./train.json: 644it [46:17,  4.87s/it]./train.json: 645it [46:22,  4.90s/it]./train.json: 646it [46:28,  5.02s/it]./train.json: 647it [46:33,  5.15s/it]./train.json: 648it [46:38,  4.98s/it]./train.json: 649it [46:44,  5.43s/it]./train.json: 650it [46:49,  5.33s/it]./train.json: 651it [46:54,  5.15s/it]./train.json: 652it [46:59,  5.07s/it]./train.json: 653it [47:03,  4.71s/it]./train.json: 654it [47:07,  4.53s/it]./train.json: 655it [47:13,  4.89s/it]./train.json: 656it [47:17,  4.85s/it]./train.json: 657it [47:22,  4.73s/it]./train.json: 658it [47:30,  5.71s/it]./train.json: 659it [47:35,  5.51s/it]./train.json: 660it [47:39,  5.06s/it]./train.json: 661it [47:44,  5.04s/it]./train.json: 662it [47:51,  5.55s/it]./train.json: 663it [47:56,  5.39s/it]./train.json: 664it [48:01,  5.49s/it]./train.json: 665it [48:08,  5.88s/it]./train.json: 666it [48:13,  5.49s/it]./train.json: 667it [48:21,  6.42s/it]./train.json: 668it [48:28,  6.60s/it]./train.json: 669it [48:34,  6.45s/it]./train.json: 670it [48:38,  5.69s/it]./train.json: 670it [48:38,  4.36s/it]
In the Matrigel invasion assay, knockdown of CCR1 and inhibition of the ERK and Rac signaling pathways significantly decreased the number of invading cells. These results demonstrated for the first time that the interaction of CCR1 with CCL5 caused by increased expression of CCR1 promotes invasion of PC3PR cells by increasing secretion of MMPs 2 and 9 and by activating ERK and Rac signaling. These data suggest that P-Rex1 has an influence on physiological migratory processes, such as invasion of cancer cells, both through effects upon classical Rac1-driven motility and a novel association with RTK signalling complexes. Activated PAR1 induced RhoA and Rac1 phosphorylation, and subsequent overexpression of myosin IIA and filamin B which are stress fiber components that were identified by PMF analysis of peptide mass data obtained by MALDI-TOF/MS measurement.  These results demonstrate that PAR1 activation induces cell morphological change associated with cell motility via Rho family activation and cytoskeletal protein overexpression, and has a critical role in gastric cancer cell invasion and metastasis. Rac1 was found to be required for actopaxin-induced matrix degradation whereas inhibition of myosin contractility promoted degradation in the phosphomutant-expressing Quint cells, indicating that a balance of Rho GTPase signaling and regulation of cellular tension are important for the process. Taken together, this study demonstrates a new role for actopaxin phosphorylation in matrix degradation and cell invasion via regulation of Rho GTPase signaling. BART inhibits pancreatic cancer cell invasion by Rac1 inactivation through direct binding to active Rac1 We report that Binder of Arl Two (BART) plays a role in inhibiting cell invasion by regulating the activity of the Rho small guanosine triphosphatase protein Rac1 in pancreatic cancer cells. BART interacts with active forms of Rac1, and the BART-Rac1 complex localizes at the leading edges of migrating cancer cells. Suppression of BART increases active Rac1, thereby increasing cell invasion. Treatment of pancreatic cancer cells in which BART is stably knocked down with a Rac1 inhibitor decreases invasiveness. Thus, BART-dependent inhibition of cell invasion is likely associated with decreased active Rac1. The Rac1 inhibitor inhibits the lamellipodia formation that is stimulated by suppression of BART. Our results imply that BART regulates actin-cytoskeleton rearrangements at membrane ruffles through modulation of the activity of Rac1, which, in turn, inhibits pancreatic cancer cell invasion. It has been reported as an important inducer of cancer cell migration and invasion, with underlying molecular mechanisms involving the signalling mediated by its juxtamembrane domain, the secretion of matrix metalloproteases to the extracellular media, and the cleavage of a P-cadherin soluble form with pro-invasive activity. Intracellularly, this protein interferes with the endogenous cadherin/catenin complex, inducing p120-catenin delocalization to the cytoplasm, and the consequent activation of Rac1/Cdc42 and associated alterations in the actin cytoskeleton. Targeted down-regulation of RhoC led to sustained activation of Rac1 GTPase and morphological, molecular and phenotypic changes reminiscent of epithelial to mesenchymal transition. We also find that Rac1 GTPase mediates tight binding of prostate cancer cells to bone marrow endothelial cells and promotes retraction of endothelial cells required for tumor cell diapedesis. Finally, Rac1 leads to 1 integrin activation, suggesting a mechanism that Rac1 can mediate tight binding with endothelial cells. Together, our data suggest that Rac1 GTPase is key mediator of prostate cancer cell-bone marrow endothelial cell interactions. Furthermore, expression of dominant-negative Rac1 (T17N) could largely block EGF-induced PI3K/Akt-PAK1 activation and cell migration. Our study demonstrated that EGF-induced cell migration involves a cascade of signalling events, including activation of Rac1, generation of ROS and subsequent activation of PI3K/Akt and PAK1. Small GTPase proteins, including RhoA, RhoB, RhoC, Rac1, and cdc42, are important molecules for linking cell shape and cell-cycle progression because of their role in both cytoskeletal arrangements and mitogenic signaling. The suppression of MMP-2 expression by CTXG led to an inhibition of SW620 cells invasion and migration by inactivating Rac1 and Cdc42 but not RhoA GTPase. In conclusion, our data demonstrate that CTXG exerted anti-invasion action in SW620 cells by targeting MMP-2 though regulating the activities of Rac1, Cdc42 and their downstream transcriptional factor AP-1. ctivation of H-Ras and Rac1 correlates with epidermal growth factor-induced invasion in Hs578T and MDA-MB-231 breast carcinoma cells We have previously shown that H-Ras, but not N-Ras, induces an invasive phenotype mediated by small GTPase Rac1 in MCF10A human breast epithelial cells. Moreover, siRNA-knockdown of Rac1 significantly inhibited the EGF-induced invasiveness in these cells. Our data demonstrate that the activation of H-Ras and the downstream molecule Rac1 correlates with EGF-induced breast cancer cell invasion, providing important information on the regulation of malignant progression in mammary carcinoma cells. At 50% growth-inhibiting concentration, icariin significantly suppressed tumor cells migration and invasion, which were traceable to down-regulation of Rac1 and VASP.  These results indicate that icariin exerts negative effects on tumor cell invasion and migration via the Rac1-dependent VASP pathway and may be a potential anti-cancer drug. RhoGDI2 modulates the invasiveness and metastatic ability of cancer cells through regulation of Rac1 activity. We also showed that GBM cells secrete Sema3A endogenously, and RNA interference-mediated downregulation of Sema3A inhibits migration and alters cell morphology that is dependent on Rac1 activity. LMO1 and Dock180, a bipartite Rac1 guanine nucleotide exchange factor, promote human glioma cell invasion Here, we report for the first time that engulfment and cell motility 1 (ELMO1) and dedicator of cytokinesis 1 (Dock180), a bipartite Rac1 guanine nucleotide exchange factor (GEF), are evidently linked to the invasive phenotype of glioma cells. Inhibition of endogenous ELMO1 and Dock180 expression significantly impeded glioma cell invasion in vitro and in brain tissue slices with a concomitant reduction in Rac1 activation. Members of the Rac family of small GTPases are known to act as regulators of actin cytoskeletal structures and strongly influence the cellular processes of integrin-mediated adhesion and migration. Even though hyperactivated Rac proteins have been shown to influence metastatic processes, these proteins have never been directly linked to metastatic progression.  We show that increased activation of Rac proteins directly correlates with increasing metastatic potential in a panel of cell variants derived from a single metastatic breast cancer cell line (MDA-MB-435). Expression of a dominant active Rac1 or a dominant active Rac3 resulted in a more invasive and motile phenotype. Moreover, expression of either dominant negative Rac1 or dominant negative Rac3 into the most metastatic cell variant resulted in decreased invasive and motile properties. This study correlates endogenous Rac activity with high metastatic potential and implicates Rac in the regulation of cell migration and invasion in metastatic breast cancer cells. Taken together, these results suggest a role for both the Rac1 and Rac3 GTPases in human breast cancer progression.
end of process!
